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Meningiomas	  are	  the	  most	  common	  central	  nervous	  system	  primary	  tumors.	  
Mutations	  in	  the	  tumor	  suppressor	  gene	  Neurofibromin	  2	  (NF2),	  located	  on	  
chromosome	  22	  (Chr22),	  are	  present	  in	  40-­‐50%	  of	  sporadic	  meningiomas.	  In	  a	  
subset	  of	  non-­‐NF2-­‐mutant	  meningiomas,	  recent	  studies	  have	  identified	  
tumorigenesis	  driver	  mutations	  in	  the	  genes	  TRAF7,	  AKT1,	  KLF4,	  and	  SMO.	  However,	  
the	  genetic	  basis	  for	  the	  marked	  clinical	  and	  histological	  heterogeneity	  that	  exists	  
among	  NF2-­‐mutant/Chr22-­‐loss	  meningiomas	  remains	  to	  be	  established.	  In	  this	  
study,	  we	  utilized	  next-­‐generation	  sequencing	  techniques	  to	  identify	  and	  screen	  a	  
large	  cohort	  of	  NF2-­‐mutant/Chr22-­‐loss	  meningiomas	  for	  concurrent	  co-­‐driver	  
mutations	  in	  novel	  genes	  that	  may	  contribute	  to	  the	  observed	  clinical	  and	  
histological	  heterogeneity	  of	  these	  tumors.	  	  
We	  identified	  25	  NF2-­‐mutant/Chr22-­‐loss	  meningiomas	  that	  harbored	  concurrent	  
somatic	  mutations	  in	  the	  SMARCB1	  gene.	  SMARCB1	  codes	  for	  a	  component	  of	  the	  
SWI/SNF	  complex	  and	  is	  involved	  in	  epigenetic	  modification	  via	  nucleosome	  
modulation	  and	  chromatin	  remodeling.	  SMARCB1	  is	  also	  known	  to	  interact	  with	  
	  
GLI1,	  an	  important	  effector	  of	  the	  Hedgehog	  pathway,	  and	  EZH2,	  a	  member	  of	  the	  
Polycomb-­‐group	  proteins	  that	  is	  capable	  of	  epigenetically	  silencing	  gene	  expression	  
via	  histone	  methylation.	  SMARCB1	  somatic	  mutations	  have	  previously	  been	  
associated	  with	  the	  highly	  aggressive	  malignant	  rhabdoid	  tumors	  and	  germline	  
variants	  have	  previously	  been	  identified	  as	  the	  driver	  mutation	  responsible	  for	  
familial	  schwannomatosis.	  	  Notably,	  a	  subset	  of	  patients	  with	  familial	  
schwannomatosis	  develop	  multiple	  meningiomas	  as	  part	  of	  their	  disease	  course.	  
We	  performed	  RNA	  expression	  analysis	  to	  determine	  gene	  expression	  differences	  in	  
SMARCB1-­‐mutant	  meningiomas	  versus	  non-­‐SMARCB1-­‐mutant	  meningiomas.	  
Unsupervised	  hierarchical	  clustering	  demonstrated	  that	  the	  expression	  profiles	  of	  
SMARCB1-­‐mutant	  meningiomas	  cluster	  similarly	  to	  other	  NF2-­‐mutant/Chr22	  loss	  
meningiomas.	  However,	  within	  this	  superfamily,	  SMARCB1-­‐mutant	  meningiomas	  
form	  distinct	  subgroups.	  This	  differential	  clustering	  is	  due,	  at	  least	  in	  part,	  to	  
increased	  GLI1	  and	  EZH2	  expression	  suggesting	  that	  SMARCB1-­‐mutant	  tumors	  
represent	  a	  distinct	  genetic	  subtype	  of	  NF2-­‐mutant	  meningiomas.	  	  
Genomic-­‐clinical	  correlates	  for	  SMARCB1-­‐mutant	  tumors	  showed	  no	  significant	  
differences	  in	  this	  cohort	  in	  age	  at	  time	  of	  surgery	  (median	  =	  64	  years),	  gender	  
predilection	  (80%	  female),	  or	  low-­‐grade	  histologic	  subtype	  when	  compared	  to	  the	  
natural	  history	  literature.	  However,	  the	  SMARCB1-­‐mutant	  meningiomas	  were	  
predominantly	  midline	  tumors	  (71%)	  with	  increased	  propensity	  to	  being	  high-­‐
grade	  lesions	  (36%),	  despite	  remarkable	  chromosomal	  stability.	  These	  clinical	  
findings	  strongly	  paralleled	  our	  genetic	  data	  suggesting	  that	  increased	  expression	  of	  
	  
GLI	  and	  EZH2	  may,	  respectively,	  contribute	  to	  the	  midline	  tumor	  location	  and	  serve	  
as	  a	  substitute	  for	  widespread	  chromosomal	  instability	  in	  high-­‐grade	  lesions.	  	  
These	  results	  demonstrate	  that	  SMARCB1-­‐mutant	  meningiomas	  represent	  a	  
genetically	  and	  phenotypically	  distinct	  sub-­‐group	  of	  NF2-­‐mutant	  meningiomas	  and	  
partially	  contribute	  to	  the	  observed	  clinical	  heterogeneity	  of	  convexity	  lesions.	  This	  
study	  also	  suggests	  potential	  targets	  for	  therapeutic	  interventions	  that	  warrant	  
future	  investigation.	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Meningiomas	  –	  Clinical	  and	  Histological	  Overview	  
	  
Meningiomas	  are	  central	  nervous	  system	  (CNS)	  tumors	  that	  arise	  from	  the	  
meninges.	  They	  are	  the	  most	  common	  primary	  CNS	  tumor	  (35%)	  with	  a	  prevalence	  
of	  approximately	  170,000	  cases	  and	  approximately	  22,000	  new	  cases	  diagnosed	  
annually	  in	  the	  United	  States(1).	  The	  World	  Health	  Organization	  (WHO)	  classifies	  
meningiomas	  as	  grade	  I	  to	  grade	  III	  based	  on	  morphologic	  and	  histopathological	  
criteria(2).	  Histologic	  WHO	  grade	  I	  lesions	  are	  benign	  and	  are	  by	  far	  the	  most	  
common.	  However,	  while	  previous	  studies	  estimated	  that	  >90%	  of	  meningiomas	  
were	  grade	  I	  (3,	  4),	  contemporary	  reports	  and	  retrospective	  analysis	  of	  previous	  
studies	  now	  estimate	  that	  grade	  I	  lesions	  more	  likely	  comprise	  approximately	  80%	  
(5-­‐7).	  Grade	  I	  lesions	  can	  be	  further	  classified	  by	  histologic	  characteristics	  into	  the	  
following	  subtypes:	  meningothelial,	  fibrous,	  transitional,	  psammomatous,	  
angiomatous,	  microcystic,	  secretory,	  lymphoplasmacyte-­‐rich,	  or	  metaplastic	  
meningioma	  (5,	  8).	  Grade	  I	  lesions	  are	  generally	  amenable	  to	  surgical	  resection.	  
However,	  even	  with	  complete	  surgical	  resection,	  these	  lesions	  have	  a	  relatively	  high	  
rate	  of	  recurrence	  (10-­‐18%)	  at	  5	  years	  after	  surgery	  (9,	  10).	  Grade	  II	  meningiomas	  
(“atypical”)	  are	  thought	  to	  comprise	  5-­‐20%	  of	  all	  meningiomas	  (3,	  5-­‐8,	  11).	  These	  
lesions	  are	  histologically	  characterized	  by	  an	  increased	  mitotic	  index	  (>	  4	  per	  10	  
high-­‐powered	  fields)	  and	  the	  presence	  of	  foci	  of	  necrosis	  (2,	  8).	  Clear-­‐cell	  and	  
choroid	  variants	  are	  also	  characterized	  as	  Grade	  II	  lesions	  (5,	  8).	  Grade	  III	  lesions	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(“anaplastic”),	  comprising	  only	  1-­‐5%	  of	  all	  meningiomas	  (3,	  5,	  6),	  are	  characterized	  
by	  a	  significantly	  greater	  mitotic	  index	  (>	  20	  per	  10	  high-­‐powered	  fields)	  and	  
multiple,	  large	  foci	  of	  necrosis	  (5,	  8).	  Rhabdoid	  and	  papillary	  meningiomas	  are	  also	  
considered	  grade	  III	  (5).	  
	  
Like	  grade	  I	  meningiomas,	  grade	  II	  and	  grade	  III	  lesions	  can	  be	  amenable	  to	  surgical	  
resection;	  however,	  these	  higher-­‐grade	  tumors	  have	  even	  higher	  rates	  of	  recurrence	  
and	  carry	  significantly	  more	  grave	  prognoses.	  Grade	  II	  meningiomas	  have	  a	  
reported	  40%	  recurrence	  rate	  at	  5	  years	  following	  total	  resection	  and	  a	  5	  and	  10-­‐
year	  overall	  survival	  rate	  of	  78-­‐95%	  and	  53-­‐79%,	  respectively,	  even	  with	  optimal	  
surgical	  treatment	  (5,	  11-­‐13).	  Grade	  III	  lesions	  have	  a	  recurrence	  rate	  approaching	  
80%	  at	  5	  years	  following	  total	  resection	  and	  with	  a	  5	  and	  10-­‐year	  overall	  survival	  
rate	  of	  only	  44-­‐64%	  and	  14-­‐34%,	  respectively,	  following	  treatment.	  One	  factor	  
contributing	  to	  the	  poor	  prognosis	  carried	  by	  the	  high-­‐grade	  meningiomas	  is	  the	  
lack	  of	  effective	  chemotherapeutic	  therapies	  to	  supplement	  surgical	  and	  radiation	  
interventions	  (14).	  It	  is	  believed	  that	  the	  majority	  of	  these	  higher-­‐grade	  tumors	  
arise	  de	  novo;	  however,	  there	  are	  a	  number	  of	  case	  reports	  that	  describe	  the	  
progression	  of	  grade	  I	  lesions	  to	  both	  atypical	  and	  anaplastic	  variants	  (15,	  16).	  	  
	  
In	  addition	  to	  the	  WHO	  grading	  system,	  meningiomas	  can	  also	  be	  classified	  by	  their	  
location	  within	  the	  CNS.	  The	  majority	  (90-­‐98%)	  are	  found	  intracranially,	  with	  only	  
2-­‐10%	  occurring	  in	  the	  spine	  (4,	  8).	  Within	  the	  cranium,	  meningiomas	  can	  be	  
described	  as	  either	  “skull	  base”	  or	  “convexity”	  lesions.	  Skull	  base	  lesions	  arise	  from	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the	  meninges	  that	  overlie	  the	  boney	  surfaces	  of	  the	  sphenoid	  wing,	  olfactory	  groove,	  
suprasellar	  region,	  or	  posterior	  cranial	  fossa.	  Convexity	  meningiomas	  (including	  
falcine	  and	  parasagittal	  lesions)	  are	  tumors	  that	  grow	  from	  the	  meninges	  over	  the	  
cerebral	  hemispheres.	  
	  
Classified	  by	  location,	  convexity	  meningiomas	  are	  the	  most	  common	  (approximately	  
25-­‐40%)	  (17,	  18).	  Given	  their	  locations	  on	  the	  surface	  of	  the	  brain,	  convexity	  lesions	  
are	  generally	  more	  amenable	  to	  surgical	  resection	  compared	  to	  skull	  base	  tumors.	  
However,	  multiple	  studies	  have	  identified	  convexity	  meningiomas	  as	  having	  
significantly	  increased	  propensities	  to	  recur	  and	  to	  present	  as	  de	  novo	  grade	  II	  or	  
grade	  III	  lesions	  (18-­‐22).	  In	  other	  words,	  the	  tumors	  that	  have	  the	  easier	  surgical	  
approach	  are	  the	  ones	  with	  an	  increased	  likelihood	  of	  being	  malignant.	  
Furthermore,	  there	  is	  marked	  heterogeneity	  among	  convexity	  meningiomas	  in	  
terms	  of	  location,	  histological	  type,	  grade,	  and	  propensity	  to	  recur.	  	  
	  
The	  primary	  treatment	  for	  both	  benign	  and	  higher-­‐grade	  meningiomas	  remains	  
surgical	  resection.	  Radiation	  therapy	  has	  been	  frequently	  used	  as	  an	  adjuvant	  to	  
surgical	  resection;	  however,	  its	  use	  remains	  controversial	  (9,	  10,	  12,	  23).	  Further,	  








With	  the	  recent	  developments	  in	  next-­‐generation	  sequencing	  technologies,	  the	  field	  
of	  cancer	  and	  clinical	  genetics	  has	  experienced	  a	  period	  of	  exponential	  growth	  (24-­‐
26).	  These	  technologies	  now	  allow	  for	  a	  rapid,	  unbiased,	  and	  comprehensive	  
analysis	  of	  the	  genetic	  mutations	  underlying	  tumorigenesis	  (27)	  and	  inheritable	  
disorders	  (28-­‐31).	  Research	  utilizing	  these	  techniques	  has	  advanced	  our	  
understanding	  of	  the	  pathogenesis	  of	  numerous	  cancers	  including	  leukemias	  and	  
lymphomas	  (32-­‐42),	  melanoma	  (43,	  44),	  renal	  cell	  carcinoma	  (45,	  46),	  head	  and	  
neck	  squamous	  cell	  carcinoma	  (47-­‐49),	  breast	  carcinomas	  (50-­‐53),	  hepatocellular	  
carcinoma	  (54,	  55),	  lung	  (56,	  57),	  esophageal	  (58-­‐61),	  pancreatic	  (62),	  prostate	  
(63),	  gynecologic	  cancers	  (64-­‐66),	  and	  others.	  
	  
CNS	  tumors	  have	  also	  been	  studied	  using	  these	  methods,	  leading	  to	  the	  
identification	  of	  genetic	  mutations	  associated	  with	  ependymomas	  (67),	  
medulloblastomas	  (68),	  craniopharyngiomas	  (69),	  solitary-­‐fibrous	  tumors	  (70),	  and	  
gliomas	  (71,	  72).	  	  
	  
The	  identification	  of	  the	  genetic	  aberrations	  associated	  with	  tumor	  development	  not	  
only	  helps	  define	  the	  pathophysiology	  and	  molecular	  mechanisms	  driving	  
tumorigenesis,	  but	  also	  identifies	  potential	  therapeutic	  targets	  for	  
chemotherapeutic	  and	  immunotherapeutic	  regimens	  (73).	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Broadly,	  the	  genetic	  aberrations	  associated	  with	  various	  cancers	  can	  be	  classified	  as	  
either	  “germline”	  or	  “somatic”.	  Germline	  mutations	  are	  detectable	  and	  heritable	  
variations	  in	  the	  germ	  cell	  lineage	  and	  are	  transmitted	  to	  offspring	  following	  the	  
usual	  patterns	  and	  rules	  of	  inheritance.	  A	  germline	  mutation	  results	  in	  a	  
constitutional	  mutation	  in	  the	  offspring	  -­‐	  that	  is,	  the	  mutation	  is	  present	  in	  every	  
cell.	  The	  role	  that	  the	  inherited	  genetic	  aberration	  plays	  in	  the	  development	  of	  
cancer	  depends	  on	  the	  characteristics	  and	  downstream	  effects	  of	  the	  mutation,	  as	  
well	  the	  expression	  and	  inherent	  role	  of	  the	  mutated	  gene	  and	  the	  pathophysiology	  
of	  the	  disease	  state.	  For	  example,	  Li-­‐Fraumeni	  syndrome	  is	  caused	  by	  a	  germline	  
loss	  of	  the	  p53	  gene	  which	  results	  in	  the	  development	  of	  a	  variety	  of	  cancers	  (74).	  
The	  effect	  of	  the	  inherited	  mutation	  may	  also	  be	  a	  very	  specific,	  stereotyped	  
tumorigenesis	  –	  as	  in	  familial	  adenomatous	  polyposis	  syndrome,	  caused	  by	  a	  
germline	  mutation	  in	  the	  APC	  gene	  (75).	  	  
	  
In	  contrast	  to	  germline	  mutations,	  somatic	  (also	  termed	  “acquired”)	  mutations	  are	  
not	  heritable	  and	  are	  only	  present	  in	  cells	  that	  originate	  from	  the	  primarily	  affected	  
cell.	  These	  mutations	  may	  initially	  affect	  only	  one	  copy	  of	  the	  gene	  and	  can	  arise	  
from	  DNA	  damage	  or	  errors	  during	  DNA	  replication.	  A	  well-­‐characterized	  somatic	  
mutation	  associated	  with	  cancer	  is	  the	  BRAF	  V600E	  variant	  that	  was	  found	  to	  drive	  
the	  tumorigenesis	  of	  melanomas	  (76).	  
	  
An	  example	  helps	  to	  clarify	  the	  distinction	  between	  germline	  and	  somatic	  mutations	  
as	  they	  pertain	  to	  tumor	  development.	  In	  a	  patient	  with	  lung	  adenocarcinoma,	  a	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sample	  of	  the	  tumor	  is	  genetically	  analyzed	  and	  is	  found	  to	  harbor	  a	  mutation	  in	  
gene	  X.	  If	  this	  mutation	  is	  a	  germline	  mutation,	  then	  1.)	  the	  patient	  will	  have	  
inherited	  this	  mutation	  from	  his	  parents;	  2.)	  this	  exact	  mutation	  will	  be	  present	  in	  
the	  DNA	  of	  all	  the	  patient’s	  cells,	  including	  non-­‐tumor	  cells	  (white	  blood	  cells,	  for	  
example);	  and	  3.)	  the	  patient	  may	  pass	  this	  mutation	  on	  to	  offspring.	  In	  contrast,	  if	  
the	  mutation	  in	  gene	  X	  is	  a	  somatic	  mutation,	  then	  1.)	  the	  mutation	  will	  not	  have	  
been	  inherited	  but	  rather	  will	  have	  arisen	  within	  a	  cell	  within	  the	  patient’s	  lungs,	  
either	  de	  novo	  or	  in	  response	  to	  some	  environmental	  factor	  –	  perhaps	  as	  a	  result	  of	  
exposure	  to	  cigarette	  smoke	  2.)	  this	  mutation	  will	  not	  be	  present	  in	  the	  DNA	  of	  
other,	  non-­‐tumor	  cells	  within	  in	  the	  patient	  (white	  blood	  cells,	  for	  example);	  and	  3.)	  
the	  patient	  will	  not	  pass	  this	  mutation	  on	  to	  offspring.	  
	  
	  
Genetics	  of	  Meningiomas	  
	  
Investigations	  of	  the	  genetics	  of	  meningiomas	  have	  focused	  on	  both	  heritable,	  
syndromic	  cases	  and	  sporadic	  lesions.	  	  The	  results	  of	  these	  studies	  have	  identified	  a	  
number	  of	  genetic	  mutations	  associated	  with	  CNS	  meningiomas	  and	  have	  
demonstrated	  that	  both	  germline	  and	  somatic	  aberrations	  can	  play	  a	  role	  in	  





Germline	  Mutations	  Associated	  with	  Meningiomas	  
	  
The	  most	  notable	  inherited	  syndrome	  associated	  with	  meningiomas	  is	  
Neurofibromatosis	  type	  2,	  an	  autosomal	  dominant	  disorder	  characterized	  by	  the	  
development	  of	  multiple	  neoplastic	  lesions.	  Neurofibromatosis	  type	  2	  results	  from	  a	  
mutation	  in	  the	  tumor	  suppressor	  gene	  Neurofibromin	  2	  (NF2,	  merlin),	  which	  is	  
located	  on	  the	  long	  arm	  of	  chromosome	  22	  (Chr22)	  (Chr22q12.2)	  (12,	  77).	  	  NF2	  
encodes	  the	  tumor	  suppressor	  protein	  Merlin,	  which	  localizes	  to	  the	  cell	  membrane	  
and	  has	  been	  implicated	  in	  regulating	  cell	  growth	  and	  motility	  (12,	  78-­‐80).	  In	  
addition	  to	  the	  pathognomonic	  bilateral	  acoustic	  neuromas	  (81-­‐83),	  approximately	  
50%	  of	  patients	  develop	  meningiomas	  (84,	  85).	  Interestingly,	  many	  patients	  with	  
Neurofibromatosis	  type	  2	  associated	  meningiomas	  will	  have	  multiple	  lesions	  
(meningiomatosis)	  (84,	  86).	  Patients	  with	  Neurofibromatosis	  type	  2	  also	  tend	  to	  
develop	  meningiomas	  that	  both	  occur	  at	  an	  earlier	  age	  and	  are	  more	  frequently	  
high-­‐grade	  compared	  to	  patients	  who	  develop	  non-­‐syndromic,	  sporadic	  tumors	  (86-­‐
88).	  These	  findings	  established	  a	  role	  for	  NF2	  mutations	  in	  the	  development	  of	  
meningiomas;	  however,	  a	  specific	  mechanism	  of	  NF2	  mutations	  in	  the	  development	  
and	  progression	  of	  higher-­‐grade	  lesions	  has	  not	  been	  elucidated	  (5,	  12).	  
	  
Aside	  from	  the	  NF2	  mutation,	  there	  is	  only	  a	  short	  list	  of	  other	  germline	  mutations	  
that	  have	  been	  associated	  with	  heritable	  meningiomatosis.	  These	  studies	  comprise	  
only	  a	  handful	  of	  case	  reports	  and	  series	  that	  describe	  a	  small	  number	  of	  families.	  Of	  
these,	  the	  most	  consistently	  reported	  mutated	  gene	  is	  SMARCB1	  -­‐	  SWI/SNF	  related,	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matrix	  associated,	  actin	  dependent	  regulator	  of	  chromatin,	  subfamily	  b,	  member	  1.	  
SMARCB1	  (discussed	  in	  detail	  below)	  is	  located	  on	  the	  long	  arm	  of	  Chr22	  (22q11.23)	  
and	  is	  thought	  to	  act	  as	  a	  tumor	  suppressor.	  Germline	  mutations	  in	  SMARCB1	  have	  
been	  associated	  with	  the	  development	  of	  malignant	  rhabdoid	  tumors	  of	  the	  kidney,	  
atypical	  teratoid/rhabdoid	  tumors	  (AT/RT)	  of	  the	  CNS,	  and	  extra-­‐renal	  rhabdoid	  
tumors	  (89-­‐92).	  	  
	  
Germline	  SMARCB1	  mutations	  have	  also	  been	  shown	  to	  play	  a	  role	  in	  familial	  
schwannomatosis	  –	  a	  form	  of	  neurofibromatosis	  characterized	  by	  multiple	  
schwannomas,	  but	  without	  bilateral	  vestibular	  schwannomas	  (93-­‐95).	  
Approximately	  50%	  of	  patients	  with	  familial	  schwannomatosis	  harbor	  a	  germline	  
loss-­‐of-­‐function	  mutation	  in	  SMARCB1	  (96).	  A	  subset	  of	  patients	  with	  SMARCB1-­‐
associated	  schwannomatosis	  also	  develop	  multiple	  meningiomas	  (97-­‐99).	  
Interestingly,	  one	  study	  reported	  that	  intracranial	  meningiomas	  associated	  with	  
germline	  SMARCB1	  mutations	  have	  a	  predilection	  to	  form	  along	  the	  falx	  cerebri	  –	  a	  
midline	  meningeal	  fold	  that	  separates	  the	  cerebral	  hemispheres	  (99).	  
	  
	  
Somatic	  Mutations	  Associated	  with	  Meningiomas	  
	  
Somatic	  genetic	  mutations	  play	  a	  role	  in	  the	  development	  of	  meningiomas	  that	  arise	  
sporadically	  –	  i.e.	  without	  a	  familial	  predisposition.	  Compared	  with	  germline	  
mutations,	  sporadic	  mutations	  give	  rise	  to	  more	  variable	  and	  non-­‐syndromic	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disorders	  that	  challenge	  specific	  characterization.	  	  There	  are,	  however,	  similarities	  
in	  the	  gene	  mutations	  associated	  with	  sporadic	  meningiomas.	  Not	  surprisingly,	  just	  
as	  germline	  NF2	  mutations	  are	  associated	  with	  syndrome	  meningioma	  formation,	  
approximately	  40-­‐50%	  of	  all	  sporadic	  meningiomas	  have	  somatic	  mutations	  in	  the	  
tumor	  suppressor	  gene	  NF2	  and/or	  loss	  of	  chromosome	  22	  (Chr22)(5,	  8,	  12,	  100-­‐
103).	  As	  described	  above,	  NF2	  is	  located	  on	  the	  long	  arm	  of	  Chr22	  (Chr22q12.2)	  (12,	  
77).	  	  
	  
Mutations	  in	  NF2	  /	  Chr22-­‐loss	  may	  initiate	  meningioma	  tumorigenesis,	  but	  may	  not	  
necessarily	  drive	  tumor	  progression	  to	  higher-­‐grade	  lesions	  (5,	  12).	  However,	  other	  
large-­‐scale	  chromosomal	  abnormalities	  may	  be	  involved	  in	  tumor	  progression.	  
Some	  chromosomal	  abnormalities	  have	  been	  associated	  with	  higher-­‐grade	  lesions	  
include	  loss	  of	  Chr1p,	  6q,	  9p,	  10q,	  14q,	  18q	  and	  gain	  of	  Chr1q	  9q,	  12q,	  15q,	  17q,	  20q	  
(104-­‐107).	  However,	  the	  precise	  genes	  responsible	  for	  either	  the	  progression	  of	  
grade	  I	  meningiomas	  to	  higher-­‐grade	  lesions	  or	  the	  de	  novo	  formation	  of	  atypical	  
and	  anaplastic	  meningiomas	  have	  not	  been	  identified	  (5,	  12).	  Further,	  while	  
mutations	  in	  NF2	  and/or	  loss	  of	  Chr22	  have	  been	  identified	  in	  a	  large	  percentage	  of	  
meningiomas,	  approximately	  50-­‐60%	  of	  sporadic	  meningiomas	  do	  not	  harbor	  these	  
genetic	  aberrations.	  	  
	  
Recent	  studies	  have	  begun	  to	  examine	  the	  genetic	  mutations	  responsible	  for	  the	  
formation	  of	  non-­‐NF2	  /	  non-­‐Chr22-­‐loss	  sporadic	  meningiomas.	  In	  2013,	  a	  study	  by	  
Clark	  et	  al.	  identified	  mutations	  in	  TRAF7,	  AKT1,	  KLF4,	  or	  SMO	  in	  60%	  of	  non-­‐NF2	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meningiomas	  (101).	  Additional	  studies	  have	  confirmed	  the	  presence	  of	  AKT1	  or	  
SMO	  mutations	  in	  non-­‐NF2	  meningiomas	  (108)	  and	  mutations	  in	  TRAF7	  and	  KLF4	  in	  
secretory	  meningiomas	  (109).	  Clark	  et	  al.	  found	  TRAF7	  mutations	  in	  approximately	  
25%	  of	  all	  meningiomas	  (101).	  TRAF7	  codes	  for	  an	  E3	  ubiquitin	  ligase	  and	  plays	  a	  
role	  in	  the	  degradation	  of	  anti-­‐apoptotic	  molecules	  (110);	  thus	  mutations	  in	  TRAF7	  
may	  have	  a	  net	  anti-­‐apoptotic	  effect.	  	  
	  
A	  subset	  of	  meningiomas	  with	  TRAF7	  mutations	  was	  also	  found	  to	  have	  concurrent	  
mutations	  in	  either	  KLF4	  or	  AKT1	  (3).	  KLF4	  codes	  for	  a	  transcription	  factor	  that	  
plays	  a	  critical	  role	  in	  the	  regulation	  of	  cellular	  differentiation;	  it	  is	  most	  
prominently	  known	  for	  being	  one	  of	  the	  four	  transcription	  factors	  capable	  inducing	  
the	  transformation	  of	  human	  somatic	  cells	  into	  pluripotent	  stem	  cells	  (111).	  
Mutations	  in	  AKT1	  have	  been	  previously	  shown	  to	  induce	  constitutive	  activation	  of	  
the	  PI3K/AKT	  pathway	  and	  promote	  cell	  growth,	  proliferation,	  and	  survival	  (112).	  
SMO	  encodes	  Smoothened,	  a	  receptor	  in	  the	  Hedgehog	  signaling	  pathway	  (113).	  
Mutations	  in	  SMO	  have	  been	  previously	  associated	  with	  tumor	  formation	  and	  
development	  of	  basal	  cell	  carcinoma	  (114).	  	  
	  
Somatic	  SMARCB1	  mutations	  have	  also	  been	  associated	  with	  in	  8	  sporadic	  
meningiomas	  (101,	  108,	  115,	  116);	  however,	  the	  precise	  genomic	  architecture	  and	  
phenotypic	  effects	  of	  these	  mutations	  have	  not	  been	  well	  described.	  In	  2001,	  
Schmitz	  et	  al.	  was	  the	  first	  to	  report	  a	  somatic	  mutation	  in	  SMARCB1	  in	  sporadic	  
meningiomas	  (116).	  The	  investigators	  identified	  four	  meningiomas	  with	  a	  recurrent	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somatic	  mutation	  in	  SMARCB1.	  These	  tumors	  all	  also	  possessed	  a	  predicted	  loss-­‐of-­‐
function	  mutation	  in	  NF2	  and/or	  loss	  of	  a	  copy	  of	  Chr22.	  In	  2003,	  Rieske	  et	  al.	  
reported	  finding	  one	  meningioma	  (out	  of	  eighty	  screened	  via	  targeted	  Sanger	  
screening)	  that	  possessed	  a	  heterozygous,	  predictive	  loss-­‐of-­‐function	  mutations	  in	  
SMARCB1	  (115).	  However,	  no	  further	  genomic	  analysis	  (including	  NF2	  status	  or	  
demonstration	  that	  the	  identified	  mutation	  was	  indeed	  somatic)	  or	  clinical	  
correlations	  were	  provided.	  	  Clark	  et	  al.	  did	  identify	  2	  sporadic	  meningiomas	  that	  
harbored	  a	  somatic	  SMARCB1	  mutation	  (101).	  Both	  of	  these	  tumors	  also	  possessed	  a	  
concurrent	  loss-­‐of-­‐function	  mutation	  in	  NF2.	  Likewise,	  Brastianos	  et	  al.	  also	  
reported	  a	  single	  sporadic	  meningioma	  that	  possessed	  a	  somatic	  SMARCB1	  mutation	  
with	  a	  concurrent	  mutation	  in	  NF2	  (108).	  Again,	  however,	  none	  of	  these	  studies	  
provided	  any	  additional,	  in-­‐depth	  analysis	  of	  the	  genomic	  architecture	  of	  these	  
lesions	  or	  evidence	  of	  any	  effect	  on	  clinical	  presentation	  or	  tumor	  phenotype	  
conferred	  by	  the	  mutation	  in	  SMARCB1.	  	  
	  
Interestingly,	  in	  addition	  to	  discovering	  mutations	  in	  genes	  previously	  not	  known	  to	  
be	  associated	  with	  meningioma	  development,	  Clark	  et	  al.	  also	  described	  a	  pattern	  of	  
the	  genetic	  profiles	  for	  skull	  base	  meningiomas.	  That	  is,	  they	  found	  that	  specific	  
gene	  mutations	  correlated	  with	  the	  locations	  of	  meningiomas	  of	  the	  anterior	  skull	  
base.	  Specifically,	  they	  found	  that	  tumors	  originating	  from	  the	  skull	  base	  in	  the	  
posterior	  cranial	  fossa	  were	  most	  likely	  to	  harbor	  mutations	  in	  NF2	  while	  anterior	  
skull	  base	  tumors	  tended	  to	  possess	  mutations	  in	  TRAF7;	  tumors	  located	  in	  the	  
sphenoid	  wing	  predominantly	  harbored	  KLF4	  mutations;	  meningiomas	  with	  AKT1	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or	  SMO	  mutations	  were	  located	  along	  the	  midline	  of	  the	  anterior	  skull	  base	  (101).	  A	  

























Figure	  1.	  “Mutation	  Map”	  for	  Skull	  Base	  Meningiomas	  	  
Meningiomas	  arising	  along	  the	  skull	  base	  tend	  to	  possess	  a	  specific,	  stereotyped	  mutation	  driving	  
tumor	  formation	  based	  on	  tumor	  location.	  Specifically,	  meningiomas	  arising	  from	  anterior	  skull	  base	  
tended	  not	  to	  posses	  the	  NF2	  /	  Chr22-­‐loss	  mutations.	  Instead,	  tumors	  arising	  from	  the	  sphenoid	  wing	  
tended	  to	  harbor	  KLF4	  /	  TRAF7	  mutations,	  midline	  tumors	  possessed	  AKT1	  /	  TRAF7	  mutations,	  and	  
tumors	  originating	  from	  the	  olfactory	  groove	  tended	  to	  harbor	  SMO	  mutations.	  In	  contrast,	  
meningiomas	  arising	  from	  the	  posterior	  skull	  base	  tended	  to	  be	  NF2	  /	  Chr22-­‐loss.	  	  




A	  critical	  next	  step	  in	  the	  genetic	  study	  of	  meningiomas	  is	  the	  investigation	  of	  the	  
correlation	  between	  tumor	  characteristics	  and	  gene	  mutations	  in	  sporadic	  
meningiomas.	  Extending	  the	  correlation	  between	  location	  and	  genetic	  mutation	  
(shown	  by	  Clark	  et	  al.),	  we	  hypothesized	  that	  a	  “mutation	  map”	  for	  convexity	  
meningiomas	  will	  also	  help	  describe	  the	  association	  between	  specific	  gene	  
mutations	  and	  meningioma	  location.	  
	  
Clark	  et	  al.	  were	  also	  able	  to	  correlate	  the	  mutational	  profiles	  of	  meningiomas	  with	  
certain	  histologic	  characteristics	  of	  skull	  base	  lesions.	  In	  their	  investigation,	  skull	  
base	  lesions	  tended	  to	  be	  grade	  I	  lesions	  while	  convexity	  tumors	  had	  a	  higher	  
percentage	  of	  grade	  II	  and	  grade	  III	  lesions	  (101);	  this	  is	  consistent	  with	  the	  findings	  
of	  previous	  epidemiologic	  studies	  (18-­‐22,	  101).	  Further,	  they	  identified	  that	  
secretory	  meningiomas	  were	  more	  likely	  to	  harbor	  concurrent	  mutations	  in	  both	  
TRAF7	  and	  KLF4	  (101).	  Again,	  similar	  to	  the	  “mutation	  map”,	  we	  hypothesized	  that	  
correlations	  between	  the	  mutational	  profile	  and	  tumor	  phenotype	  for	  convexity	  
meningiomas	  may	  exist	  and	  can	  be	  identified	  via	  next-­‐generation	  high-­‐throughput	  
genetic	  screening	  and	  whole-­‐exome	  sequencing	  techniques.	  	  
	  
A	  number	  of	  other	  studies	  have	  attempted	  to	  identify	  the	  specific	  genes	  responsible	  
for	  the	  observed	  clinical	  and	  histological	  differences	  among	  NF2/Chr22-­‐loss	  
convexity	  meningiomas,	  the	  development	  and	  progression	  of	  higher-­‐grade	  tumors,	  
and	  tumorigenesis	  of	  non-­‐NF2	  convexity	  lesions.	  However,	  what	  is	  needed	  is	  an	  
unbiased	  genomic	  approach	  to	  investigate	  subsets	  of	  meningiomas.	  Genomic	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characterization	  of	  these	  lesions,	  including	  whole-­‐exome	  sequencing	  to	  identify	  
unique	  and/or	  concurrent	  driver	  mutations	  and	  epigenetic	  and	  expression	  analyses	  
have	  the	  potential	  to	  identify	  factors	  that:	  1.)	  account	  for	  the	  clinical	  and	  histological	  
variability	  among	  NF2-­‐loss	  convexity	  meningiomas;	  2.)	  drive	  formation	  of	  non-­‐NF2	  
convexity	  meningiomas;	  3.)	  are	  responsible	  for	  tumor	  progression	  to	  and/or	  de	  
novo	  formation	  of	  higher-­‐grade	  lesions;	  4.)	  predispose	  tumors	  to	  recur;	  5.)	  and,	  





Component	  of	  the	  SWI/SNF	  Complex	  
	  
SMARCB1	  (also	  known	  as	  SNF5,	  INI1,	  or	  BAF47)	  codes	  for	  a	  component	  of	  the	  
SWI/SNF	  complex.	  This	  gene	  is	  located	  on	  the	  long	  arm	  of	  Chr22	  (22q11.23),	  6	  
megabases	  away	  from	  the	  NF2	  locus;	  the	  gene	  contains	  nine	  exons	  and	  spans	  
approximately	  50	  kilobases	  (92).	  SMARCB1	  codes	  for	  a	  protein	  that	  is	  comprised	  of	  
three	  highly	  conserved	  regions	  –	  two	  repeat	  domains	  (Rpt1	  and	  Rpt2)	  and	  a	  C-­‐
terminal	  putative	  coiled	  coil	  domain	  (117).	  The	  precise	  role	  of	  these	  domains	  have	  
not	  been	  fully	  described.	  The	  SMARCB1	  protein	  is	  a	  known	  core	  component	  of	  the	  
SWI/SNF	  or	  BAF	  chromatin-­‐remodeling	  complex	  (118).	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The	  SWI/SNF	  complex	  regulates	  gene	  expression	  via	  ATP-­‐dependent	  nucleosome	  
modulation	  and	  subsequent	  chromatin	  remodeling	  (119-­‐121).	  Chromatin	  is	  the	  
network	  of	  DNA	  and	  histone	  proteins	  that	  packages	  DNA	  into	  chromosomes	  (122).	  A	  
nucleosome	  is	  a	  subunit	  of	  chromatin	  consisting	  of	  DNA	  wrapped	  around	  eight	  
histone	  cores.	  The	  structure	  of	  chromatin	  can	  be	  remodeled	  to	  alter	  how	  tightly	  
DNA	  is	  packaged.	  This	  remodeling	  is	  one	  method	  by	  which	  the	  cell	  regulates	  gene	  
activity	  –	  DNA	  that	  is	  tightly	  packed	  is	  less	  transcribed,	  and	  thus	  gene	  expression	  is	  
lower,	  compared	  to	  DNA	  that	  is	  loosely	  packaged,	  and	  thus	  more	  highly	  expressed	  
(121).	  	  
	  
The	  SWI/SNF	  complex	  remodels	  chromatin	  via	  mobilizing	  nucleosomes	  and	  
catalyzing	  the	  ejection	  and	  insertion	  of	  histone	  octamers	  (123).	  The	  complex	  has	  
also	  been	  demonstrated	  to	  play	  a	  role	  in	  transcription	  factor	  binding,	  further	  
highlighting	  the	  capacity	  of	  SWI/SNF	  to	  regulate	  gene	  expression	  (123,	  124).	  The	  
protein	  coded	  for	  by	  SMARCB1	  is	  a	  core	  SWI/SNF	  complex	  subunit	  that	  is	  present	  in	  
all	  known	  variants	  of	  the	  SWI/SNF	  complex;	  the	  genetic	  sequence	  of	  SMARCB1	  is	  
very	  highly	  conserved	  (118).	  The	  SMARCB1	  subunit	  has	  been	  implicated	  to	  play	  a	  
role	  in	  the	  recruitment	  of	  the	  SWI/SNF	  complex	  to	  specific	  target	  genes	  (125,	  126).	  	  
	  
Via	  its	  broad	  role	  in	  the	  regulation	  of	  DNA	  transcription,	  the	  SWI/SNF	  complex	  has	  
been	  demonstrated	  to	  play	  a	  role	  in	  numerous	  processes	  including	  DNA	  repair	  (127-­‐
129),	  cell	  cycle	  progression	  (130-­‐133),	  cell	  proliferation	  and	  differentiation	  (134-­‐
138).	  Importantly,	  there	  is	  emerging	  evidence	  that	  SWI/SNF	  complex	  also	  acts	  a	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tumor	  suppressor	  (139).	  Mutations	  to	  integral	  components	  of	  the	  complex	  have	  
been	  associated	  with	  the	  development	  of	  numerous	  tumors	  including	  various	  forms	  
of	  renal	  (140),	  pancreatic	  (141,	  142),	  hepatocellular	  (143),	  breast	  (144-­‐147),	  
ovarian	  (148,	  149),	  and	  lung	  (150-­‐153)	  cancers	  and	  medulloblastomas	  (154).	  
	  
	  
Role	  in	  Tumorigenesis	  
	  
Aberrations	  in	  the	  SMARCB1	  subunit	  of	  the	  SWI/SNF	  complex	  have	  been	  associated	  
with	  tumorigenesis.	  In	  addition	  to	  the	  association	  of	  germline	  and	  somatic	  SMARCB1	  
mutations	  with	  schwannomas	  and	  meningioma	  formation	  discussed	  above,	  loss-­‐of-­‐
function	  mutations	  in	  SMARCB1	  have	  been	  identified	  in	  malignant	  rhabdoid	  tumors	  
(89,	  90,	  92,	  155),	  chondrosarcomas,	  atypical	  teratoid/rhabdoid	  tumors	  (AT/RT)	  of	  
the	  CNS	  (156),	  epitheliod	  sarcomas	  (157),	  and	  chordomas	  (158).	  These	  mutations	  
occur	  both	  as	  somatic	  mutations	  in	  sporadic	  cases	  and	  as	  germline	  mutations	  in	  
familial	  cases,	  as	  in	  a	  condition	  termed	  rhabdoid	  predisposition	  syndrome	  (90,	  156).	  
The	  role	  of	  SMARCB1	  as	  a	  tumor	  suppressor	  has	  further	  been	  demonstrated	  in	  
animal	  studies.	  Prior	  research	  has	  found	  that	  mice	  that	  are	  heterozygous	  for	  the	  
SMARCB1	  allele	  develop	  rhabdoid-­‐like	  tumors	  of	  the	  CNS	  and	  soft	  tissues	  of	  the	  first	  
branchial	  arch	  (159-­‐162).	  	  
	  
The	  clinical	  and	  animal	  model	  results	  nicely	  parallel	  some	  of	  the	  findings	  from	  
studies	  examining	  the	  molecular	  mechanisms	  and	  pathophysiology	  of	  SMARCB1	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mutations.	  Using	  microarray	  analysis,	  one	  study	  found	  that	  the	  mRNA	  expression	  of	  
p16INK4A,	  a	  tumor	  suppressor	  molecule	  coded	  for	  by	  the	  gene	  CDKN2A,	  is	  
decreased	  as	  a	  result	  of	  SMARCB1	  inactivation	  (163).	  Loss	  of	  function	  mutations	  in	  
CDKN2A	  have	  previously	  been	  well	  described	  in	  a	  wide	  variety	  of	  cancer	  types	  
(164).	  A	  follow-­‐up	  study	  demonstrated	  that	  it	  is	  indeed	  loss	  of	  p16INK4A	  activity	  
that	  is	  required	  for	  SMARCB1	  mediated	  tumorigenesis	  in	  malignant	  rhabdoid	  tumor	  
cells	  in	  vitro	  (125).	  Additional	  studies	  have	  found	  that	  cyclin	  D1	  expression,	  a	  
protein	  that	  promotes	  cell	  cycle	  progression,	  is	  increased	  in	  SMARCB1-­‐null	  
malignant	  rhabdoid	  tumor	  cells	  and,	  further,	  that	  re-­‐expression	  of	  SMARCB1	  in	  a	  
rhabdoid	  tumor	  cell	  line	  resulted	  in	  SMARCB1	  binding	  to	  the	  cyclin	  D1	  gene	  
(CCND1)	  promoter	  leading	  to	  decreased	  cyclin	  D1	  expression	  and	  cellular	  
quiescence	  (121,	  165,	  166).	  Interestingly,	  pharmacological	  inhibition	  of	  cyclin	  D1	  
has	  been	  shown	  to	  limit	  the	  growth	  of	  malignant	  rhabdoid	  tumor	  cells.	  These	  
findings	  suggest	  that	  cyclin	  D1	  inhibitors	  may	  serve	  as	  a	  potential	  therapeutic	  
regimen	  in	  patients	  with	  SMARCB1-­‐deficient	  malignant	  rhabdoid	  tumors	  and	  
potentially	  other	  SMARCB1-­‐mutated	  tumors	  (167-­‐169).	  	  
	  
The	  SWI/SNF	  complex,	  and	  SMARCB1	  specifically,	  are	  also	  known	  to	  interact	  with	  c-­‐
Myc	  –	  a	  transcription	  factor	  and	  well	  characterized	  oncogene	  that	  is	  frequently	  
overexpressed	  in	  cancer	  (170,	  171).	  Previous	  work	  has	  demonstrated	  that	  the	  
SWI/SNF	  complex	  is	  capable	  of	  directly	  repressing	  c-­‐Myc	  expression	  (172).	  
Interestingly,	  c-­‐Myc	  expression	  has	  been	  shown	  to	  be	  increased	  in	  SMARCB1-­‐null	  
rhabdoid	  tumor	  cells,	  suggesting	  that	  c-­‐Myc	  and	  its	  downstream	  targets	  may	  play	  a	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role	  in	  SMARCB1-­‐mutant	  rhabdoid	  tumor	  as	  well	  as	  other	  SWI/SNF-­‐aberrant	  
cancers	  (121,	  165,	  173).	  
	  
Recent	  work	  has	  implicated	  the	  Hedgehog	  Pathway	  in	  SMARCB1-­‐mutant	  tumors.	  
The	  Hedgehog	  pathway	  is	  involved	  in	  embryogenesis	  and	  has	  well	  described	  roles	  
in	  limb	  development	  and	  the	  patterning	  of	  the	  midline	  structures	  (174,	  175).	  Loss	  of	  
Sonic	  Hedgehog,	  a	  key	  ligand	  of	  the	  Hedgehog	  pathway,	  results	  in	  
holoprosencephaly	  (176)	  –	  an	  embryologic	  disorder	  in	  which	  the	  forebrain	  does	  not	  
develop	  into	  two	  hemispheres.	  The	  defects	  range	  from	  severe	  which	  results	  in	  fetal	  
demise	  through	  milder	  forms	  where	  brain	  development	  is	  normal	  but	  face	  and	  eyes	  
are	  affected.	  	  Recent	  studies	  have	  identified	  aberrant	  activation	  of	  the	  Hedgehog	  
pathway	  to	  play	  a	  role	  in	  a	  number	  of	  cancer	  types.	  This	  aberrant	  activation	  
typically	  is	  the	  result	  of	  mutation	  in	  one	  or	  more	  of	  the	  upstream	  components	  of	  the	  
pathway	  (177).	  Mutations	  to	  the	  Hedgehog	  pathway	  have	  now	  been	  associated	  with	  
both	  syndromic	  and	  sporadic	  basal	  cell	  carcinomas	  (PTCH1	  (178,	  179)	  and	  SMO	  
(180,	  181)),	  medulloblastomas	  (PTCH1	  and	  SUFU	  (182)),	  and	  even	  meningiomas	  
(SMO	  (101,	  108)).	  	  
	  
GLI1	  is	  an	  important	  transcription	  factor	  of	  the	  Hedgehog	  pathway	  and	  plays	  key	  
roles	  during	  embryogenesis.	  Recently,	  the	  SMARCB1	  component	  of	  the	  SWI/SNF	  
complex	  was	  found	  to	  interact	  with	  GLI1.	  This	  study	  demonstrated	  that	  inactivation	  
of	  SMARCB1	  resulted	  in	  aberrant	  upregulation	  of	  the	  Hedgehog	  pathway	  and	  
increased	  GLI1	  mRNA	  expression	  (183).	  This	  SMARCB1-­‐null-­‐mediated	  aberrant	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increase	  in	  Hedgehog	  pathway	  signaling	  was	  necessary	  for	  the	  growth	  of	  rhabdoid	  
tumor	  cells	  (183).	  These	  results	  are	  consistent	  with	  studies	  demonstrating	  
increased	  GLI1	  expression	  in	  basal	  cell	  carcinomas	  resulting	  from	  mutations	  
upstream	  in	  the	  Hedgehog	  pathway	  (184,	  185).	  Taken	  together,	  these	  works	  
highlight	  a	  potential	  role	  for	  the	  deregulation	  of	  the	  Hedgehog	  pathway	  by	  SWI/SNF	  
component	  aberrations	  (specifically	  SMARCB1)	  in	  tumorigenesis.	  	  
	  
SMARCB1	  mutations	  may	  also	  play	  a	  role	  in	  tumorigenesis	  via	  epigenetic	  alterations.	  
Epigenetic	  alterations	  refer	  to	  somatically	  heritable	  changes	  in	  gene	  expression	  that	  
are	  the	  result	  of	  chromatin	  modification	  rather	  than	  genetic	  mutation	  (186).	  
SMARCB1	  and	  the	  SWI/SNF	  complex	  are	  capable	  of	  chromatin	  remodeling	  via	  ATP-­‐
dependent	  nucleosome	  modulation	  (119-­‐121).	  While	  numerous	  genetic	  mutations	  
and	  wide-­‐spread	  genomic	  instability	  are	  largely	  considered	  the	  hallmark	  of	  tumor	  
cells,	  recurrent	  epigenetic	  alterations	  have	  been	  also	  been	  hypothesized	  to	  play	  a	  
key	  role	  in	  tumorigenesis	  and	  tumor	  progression	  (187).	  This	  hypothesis	  suggests	  
that	  epigenetic	  changes	  that	  result	  from	  aberrations	  in	  the	  regulation	  of	  chromatin	  
remodeling	  can	  augment	  and/or	  be	  a	  substitute	  for	  widespread	  genomic	  instability	  
in	  the	  genesis	  of	  aggressive	  cancers	  and	  high-­‐grade	  tumors.	  Intriguingly,	  research	  
examining	  the	  role	  of	  SMARCB1	  mutations	  in	  the	  highly	  aggressive	  malignant	  
rhabdoid	  tumors	  supports	  this	  hypothesis.	  A	  2008	  study	  found	  that	  SMARCB1	  
inactivation	  had	  no	  effect	  on	  the	  DNA	  damage	  response	  and,	  further,	  the	  majority	  of	  
SMARCB1-­‐mutant	  tumors	  are	  remarkably	  stable,	  harboring	  relatively	  few	  genetic	  
point	  mutations	  and	  chromosomal	  alterations	  (such	  as	  large	  scale	  amplifications	  or	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deletions)	  compared	  to	  what	  one	  would	  expect	  for	  such	  an	  aggressive	  tumor	  type	  
(165).	  
	  
An	  additional	  mechanism	  by	  which	  SMARCB1	  mutations	  may	  contribute	  to	  
tumorigenesis	  is	  via	  an	  antagonistic	  interaction	  that	  exists	  between	  the	  SWI/SNF	  
complex	  and	  Polycomb-­‐group	  (PcG)	  proteins.	  PcG	  proteins	  are	  capable	  of	  
epigenetically	  silencing	  the	  expression	  of	  a	  gene	  via	  histone	  methylation,	  resulting	  
in	  chromatin	  remodeling	  (188-­‐190).	  Studies	  have	  demonstrated	  that	  the	  SWI/SNF	  
complex	  and	  PcG	  proteins	  have	  an	  antagonistic	  relationship,	  such	  that	  the	  SWI/SNF	  
complex	  is	  required	  for	  specific	  gene	  activation	  and	  the	  PcG	  proteins	  are	  required	  
for	  specific	  gene	  repression	  (191-­‐194).	  Alterations	  in	  PcG	  proteins	  (especially	  the	  
PcG	  protein	  EZH2)	  are	  associated	  with	  various	  cancers.	  Interestingly,	  EZH2	  
expression	  levels	  –	  that	  have	  been	  found	  to	  be	  elevated	  in	  numerous	  cancers	  and	  are	  
often	  correlated	  with	  advanced	  disease	  stages	  and	  poor	  clinical	  prognosis	  (195)	  –	  
are	  elevated	  in	  SMARCB1-­‐mutant	  tumors	  (194).	  Further,	  recent	  work	  has	  
demonstrated	  that	  re-­‐expression	  of	  SMARCB1	  in	  a	  SMARCB1-­‐null	  cell	  line	  results	  in	  
PcG	  expulsion	  from	  the	  CDKN2A	  locus,	  rescuing	  the	  expression	  and	  function	  of	  this	  
critical	  tumor	  suppressor	  molecule	  (191).	  In	  addition	  to	  the	  CDKN2A	  locus,	  rhabdoid	  
tumor	  cells	  lacking	  SMARCB1	  display	  widespread	  suppression	  of	  other	  PcG	  protein	  
target	  genes	  (191,	  194).	  Collectively,	  these	  findings	  demonstrate	  that	  an	  aberration	  
in	  the	  antagonistic	  relationship	  between	  EZH2	  and	  SMARCB1	  may	  be	  the	  driving	  
mechanism	  by	  which	  these	  SMARCB1-­‐mutant	  tumors	  form	  and/or	  contribute	  to	  
their	  aggressive	  nature.	  These	  results	  also	  suggest	  that	  pharmacologic	  inhibition	  of	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STATEMENT	  OF	  PURPOSE	  AND	  SPECIFIC	  AIMS	  
	  
Specific	  Aim	  I:	  Genetically	  characterize	  NF2-­‐loss	  meningiomas	  and	  identify	  additional	  
novel	  and/or	  concurrent	  activating	  or	  loss-­‐of-­‐function	  driver	  mutations	  that	  
contribute	  to	  heterogeneity	  of	  NF2-­‐loss	  tumors.	  	   	  
	  
Mutations	  in	  the	  tumor	  suppressor	  gene	  Neurofibromin	  2	  (NF2,	  merlin;	  located	  on	  
chromosome	  22)	  are	  present	  in	  40-­‐50%	  of	  sporadic	  meningiomas.	  Recently,	  studies	  
have	  begun	  to	  examine	  the	  genetic	  mutations	  responsible	  for	  the	  remaining	  50-­‐60%	  
of	  meningiomas	  that	  do	  not	  possess	  mutations	  in	  or	  the	  loss	  of	  NF2.	  However,	  
despite	  these	  recent	  discoveries,	  no	  study	  has	  effectively	  established	  the	  genetic	  
basis	  for	  the	  marked	  clinical	  and	  histological	  heterogeneity	  that	  exists	  among	  NF2-­‐
mutant/Chr22-­‐loss	  convexity	  meningiomas.	  	  
	  
	  
Specific	  Aim	  II:	  Perform	  epigenetic	  and	  expression	  analyses	  to	  further	  genomically	  
characterize	  NF2/Chr22-­‐loss	  convexity	  meningiomas.	  
	  
Alterations	  to	  in	  gene	  expression	  can	  further	  account	  for	  the	  discrepancies	  in	  tumor	  
biology	  and	  clinical	  behavior	  as	  well	  as	  suggest	  a	  mechanism	  for	  the	  observed	  
heterogeneity	  among	  convexity	  meningiomas.	  Importantly,	  characterization	  of	  these	  
aberrant	  pathways	  and	  mechanisms	  is	  a	  critical	  step	  in	  identifying	  potential	  targets	  
24	  
for	  chemotherapeutic	  interventions	  that	  may	  one	  day	  serve	  as	  adjunctive	  therapy	  
for	  recurrent	  and	  high-­‐grade	  lesions.	  
	  
	  
Specific	  Aim	  III:	  Compare	  and	  correlate	  clinical,	  radiologic,	  and	  histological	  features	  of	  
convexity	  and	  spinal	  meningiomas	  with	  their	  genetic	  architecture.	  
	  
Clark	  et	  al.	  described	  a	  distribution	  of	  genetic	  mutation	  profiles	  for	  skull	  base	  
meningiomas	  such	  that	  meningiomas	  located	  in	  specific	  regions	  of	  the	  skull	  base	  
were	  most	  likely	  to	  possess	  mutations	  in	  a	  specific	  gene	  or	  genes.	  We	  believed	  that	  a	  
similar	  “mutation	  map”	  –	  a	  mutation	  gradient	  or	  distribution	  –	  may	  exist	  for	  
convexity	  and	  spinal	  meningiomas.	  Further,	  we	  sought	  to	  correlate	  specific	  clinical,	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RESEARCH	  DESIGN	  AND	  METHODS	  
	  
Collection	  of	  Meningioma	  Samples	  and	  Clinical	  Data	  
	  
Institutional	  Review	  Board,	  including	  the	  Yale	  Human	  Investigation	  Committee,	  
approvals	  for	  genetic	  studies	  and	  written	  consent	  from	  all	  study	  participants	  were	  
obtained	  at	  the	  participating	  institutions.	  (HIC	  Protocol	  # 9406007680).	  	  
Demographic	  information	  along	  with	  formal	  pathology	  reports,	  pre-­‐operative	  
magnetic	  resonance	  imaging	  (MRI)	  studies,	  and	  pre-­‐operative	  radiology	  reports	  
were	  collected	  from	  study	  subjects.	  Meningiomas	  of	  varying	  grades,	  histological	  
classifications,	  and	  locations	  were	  included.	  Patients	  were	  included	  regardless	  of	  
age	  or	  gender.	  Patients	  with	  tumors	  treated	  with	  radiation	  therapy	  prior	  to	  
resection	  and	  patients	  who	  exhibited	  any	  obvious	  clinical	  manifestations	  of	  
syndromic	  disease	  (Neurofibromatosis,	  etc.)	  were	  excluded	  from	  analysis	  
	  
Resected	  meningiomas	  were	  histologically	  characterized	  and	  graded	  by	  a	  board-­‐
certified	  pathologist	  according	  to	  WHO	  guidelines.	  This	  was	  performed	  either	  by	  
members	  of	  the	  Department	  of	  Pathology	  at	  the	  Yale	  School	  of	  Medicine	  or	  the	  
collaborating	  institution.	  A	  sample	  of	  tissue	  was	  then	  frozen	  and	  sent	  to	  Dr.	  Gunel’s	  




Radiographic	  information,	  including	  tumor	  location,	  was	  provided	  by	  radiology	  
reports	  and	  characterization	  by	  board-­‐certified	  radiologists	  and/or	  neurosurgeons	  
at	  participating	  institutions.	  
	  
Correlation	  between	  clinical	  information	  and	  genetic	  analyses	  were	  performed	  to	  
identify	  potential	  genetic	  and	  phenotypic	  relationships.	  All	  clinical	  correlations	  and	  
analyses	  reported	  in	  this	  study	  were	  performed	  by	  Jacob	  Baranoski.	  
	  
Nucleic	  Acid	  Isolation	  
	  
Genomic	  DNA	  and	  RNA	  were	  extracted	  from	  tumor	  tissues	  using	  QIAgen	  Allprep	  
DNA/RNA/protein	  Mini	  Kit	  (Qiagen	  Science,	  MD)	  according	  to	  the	  manufacture’s	  
standard	  protocols.	  DNA	  from	  patient	  blood	  samples	  was	  extracted	  using	  QIAgen	  
DNeasy	  Blood	  &	  Tissue	  Kit	  (Qiagen	  Science,	  MD)	  according	  to	  the	  manufacture’s	  
standard	  protocols.	  	  
	  
DNA	  extracted	  from	  tumor	  and	  blood	  samples	  underwent	  quality	  control	  metrics,	  
including	  quantification	  (via	  Nanodrop	  and/or	  PicoGreen	  analyses	  using	  standard	  
protocols),	  DNA	  re-­‐purification	  using	  QIAgen	  kits	  according	  to	  the	  manufacture’s	  
standard	  protocols,	  and	  allocation	  for	  one	  or	  more	  of	  the	  sequencing	  methods	  






Whole-­‐Exome	  Sequencing	  and	  Analysis	  
	  
Human	  solution-­‐capture	  exome	  arrays	  from	  Nimblegen/Roche	  (Roche	  Nimblegen,	  
Inc.)	  were	  used	  to	  capture	  the	  exomes	  of	  blood	  and	  tumor	  samples	  according	  to	  the	  
manufacturer’s	  protocol	  with	  modifications,	  as	  described	  previously	  by	  Bilguvar	  et	  
al.,	  2010	  (26).	  Briefly,	  genomic	  DNA	  was	  captured	  on	  a	  NimbleGen	  2.1M	  human	  
exome	  array	  according	  to	  the	  manufacturer’s	  protocols	  (Roche	  Nimblegen,	  Inc.)	  
with	  slight	  modifications	  at	  the	  Yale	  Center	  for	  Genome	  Analysis	  (YCGA)	  at	  Yale	  
University.	  Genomic	  DNA	  was	  sheared	  via	  sonication	  and	  the	  resulting	  sheared	  
fragments	  were	  ligated	  to	  adaptors.	  These	  ligated	  fragments	  were	  fractionated	  via	  
agarose	  gel	  electrophoresis	  and	  the	  desired	  size	  fragments	  were	  excised.	  Excised	  
DNA	  was	  then	  amplified	  via	  PCR,	  purified,	  and	  hybridized	  to	  the	  capture	  array	  using	  
the	  manufacturer’s	  buffer	  and	  protocol	  (Roche	  Nimblegen,	  Inc.).	  The	  array	  was	  
washed	  according	  to	  manufacture’s	  protocol,	  with	  modifications,	  and	  using	  the	  
manufacturer’s	  buffers	  (Roche	  Nimblegen,	  Inc.).	  Bound	  genomic	  DNA	  was	  eluted	  
using	  125	  mM	  NaOH	  for	  10	  min	  at	  room	  temperature,	  purified,	  and	  then	  amplified	  
via	  PCR.	  The	  captured	  DNA	  libraries	  were	  then	  sequenced	  on	  Illumina	  HiSeq	  
instruments	  using	  74	  base	  pairs	  paired-­‐end	  reads	  by	  multiplexing	  two	  tumor	  
samples	  or	  six	  blood	  samples	  per	  lane.	  Detailed	  descriptions	  of	  these	  methods	  are	  
provided	  by	  Bilguvar	  et	  al.	  (26)	  and	  Choi	  et	  al.	  (196).	  Samples	  were	  submitted	  by	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Jacob	  Baranoski	  and	  Victoria	  Clark.	  Exome	  capture	  and	  sequencing	  protocols	  were	  
performed	  by	  YCGA.	  	  
	  
Exome	  sequence	  analysis	  was	  performed	  using	  a	  bioinformatics	  pipeline	  developed	  
by	  the	  Gunel	  Laboratory	  utilizing	  in-­‐house	  written	  scripts	  as	  well	  as	  commercially	  
and	  publicly	  available	  software,	  as	  described	  previously	  by	  Clark	  et	  al.,	  2013	  (101).	  
Briefly,	  sequence	  reads	  that	  passed	  the	  Illumina	  quality	  filter	  were	  selected	  for	  
analysis	  using	  an	  in-­‐house	  written	  bioinformatics	  pipeline.	  First,	  low-­‐quality	  reads	  
were	  further	  filtered	  out	  using	  the	  FASTX-­‐Toolkit	  software	  
(http://hannonlab.cshl.edu/fastx_toolkit/)	  and	  PCR	  primer-­‐contaminated	  sequence	  
segments	  were	  trimmed	  using	  cutadapt	  software,	  version	  0.9.5	  
(http://code.google.com/p/cutadapt/).	  Selected	  reads	  were	  then	  aligned	  to	  the	  
human	  genome	  reference	  sequence	  (version	  GRCh37)	  using	  Stampy	  (version	  1.0.16)	  
(197)	  and	  BWA	  (version	  0.5.9-­‐r16)	  (198)	  software.	  PCR	  duplicates	  were	  identified	  
using	  the	  MarkDuplicates	  algorithm	  from	  Picard	  (version	  1.47,	  
http://picard.sourceforge.net/)	  and	  discarded.	  Sequence	  quality	  metrics,	  including	  
the	  fraction	  of	  unique	  read	  pairs,	  the	  fraction	  of	  aligned	  reads,	  and	  depth	  of	  
coverage,	  were	  collected	  for	  each	  sample	  via	  the	  CollectAlignmentSummaryMetrics	  
and	  CalculateHsMetrics	  algorithms	  of	  the	  Picard	  software.	  Multi-­‐sequence	  local	  
realignment	  around	  known	  sites	  was	  performed	  along	  with	  base	  quality	  score	  
recalibration	  using	  the	  Genome	  Analysis	  Toolkit	  (GATK,	  version	  1.5-­‐20)	  (199).	  Point	  
mutations,	  small	  insertions/mutations	  were	  identified	  using	  the	  UnifiedGenotyper	  
algorithm	  from	  the	  GATK	  software	  package	  (199).	  Called	  variants	  were	  filtered	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using	  quality	  metrics	  for	  allelic	  and	  sample	  depth	  of	  coverage,	  mapping	  quality,	  ratio	  
of	  reference	  and	  non-­‐reference	  allele	  reads,	  consistency	  between	  number	  of	  allelic	  
reads	  and	  haplotype	  scores,	  and	  coverage-­‐adjusted	  variant	  read	  quality.	  Finally,	  
variant	  alleles	  were	  annotated	  using	  the	  Ensembl	  database	  (version	  66)	  with	  the	  
help	  of	  Variant	  Effect	  Predictor	  (version	  2.4)	  software	  	  
(http://useast.ensembl.org/info/docs/variation/vep/vep_script.html).	  A	  detailed	  
description	  of	  these	  methods	  is	  provided	  by	  Clark	  et	  al.	  (101).	  Sequence	  files	  were	  
run	  through	  this	  pipeline	  by	  Victoria	  Clark.	  Sequence	  results	  were	  analyzed	  by	  Jacob	  
Baranoski	  and	  Victoria	  Clark.	  	  
	  
	  
Custom	  Amplicon	  Sequencing	  and	  Analysis	  	  
	  
Targeted	  sequencing	  of	  specific	  exonic	  regions	  of	  selected	  genes	  based	  on	  whole-­‐
exome	  sequencing	  results	  was	  done	  utilizing	  custom	  amplicon	  sequencing.	  Selected	  
genes	  included	  NF2,	  TRAF7,	  AKT1,	  KLF4,	  SMO,	  and	  SMARCB1.	  Genomic	  libraries	  of	  
these	  selected	  genes	  were	  created	  using	  the	  TargetRichTM	  custom	  amplicon	  kit	  
(Kailos	  Genetics).	  Selected	  genomic	  regions	  were	  targeted	  by	  PCR	  and	  adapters	  
were	  ligated	  to	  the	  ends	  of	  the	  resulting	  PCR	  products.	  These	  libraries	  were	  
amplified	  using	  barcoded	  primers,	  allowing	  for	  multiplexing.	  Libraries	  were	  pooled	  
and	  sequenced	  on	  a	  version	  2	  Illumina	  MiSeq	  using	  paired-­‐end	  150	  base	  pair	  reads.	  
Sequence	  reads	  were	  processed	  using	  a	  similar	  bioinformatics	  pipeline	  as	  for	  the	  
whole	  exome	  data	  (above).	  Variants	  were	  called	  for	  all	  samples	  using	  GATK.	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Samples	  were	  prepared	  by	  Victoria	  Clark.	  Sequencing	  protocols	  were	  performed	  by	  




Custom	  Molecular	  Inversion	  Probe	  Sequencing	  and	  Analysis	  
	  
Additional,	  targeted	  sequencing	  of	  exonic	  regions	  and	  exon-­‐intron	  boundaries	  of	  
selected	  genes	  based	  on	  whole-­‐exome	  sequencing	  results	  was	  done	  using	  molecular	  
inversion	  probes	  (MIPs).	  Selected	  genes	  included	  NF2,	  TRAF7,	  AKT1,	  KLF4,	  SMO,	  and	  
SMARCB1.	  The	  molecular	  inversion	  probes	  were	  designed	  and	  libraries	  were	  
generated	  as	  previously	  described	  by	  O’Roak	  et	  al.,	  2012	  (200),	  with	  slight	  
modifications.	  Briefly,	  overlapping	  probes	  were	  designed	  to	  span	  the	  exons	  and	  
exon-­‐intron	  boundaries	  of	  the	  aforementioned	  selected	  genes.	  The	  ordered	  probes	  
were	  synthesized	  by	  Integrated	  DNA	  Technologies,	  Coralville,	  IA.	  Probes	  were	  
pooled	  equimolarly	  and	  phosphorylated.	  Probe	  hybridization	  was	  optimized	  via	  
using	  serial	  dilutions	  of	  phosphorylated	  and	  pooled	  probes.	  Multiplexed	  DNA	  
capture	  of	  the	  targeted	  sequences	  of	  the	  selected	  genes	  was	  performed	  via	  probe	  
hybridization,	  gap	  filling	  and	  ligation,	  and	  exonuclease	  digestion.	  150	  ng	  of	  genomic	  
DNA	  for	  each	  sample	  was	  used.	  The	  captured	  DNA	  was	  amplified	  using	  barcoded	  
primers	  which	  allowed	  for	  multiplexing.	  Libraries	  were	  cleaned	  up	  using	  AMPure	  
XP	  beads	  (Beckman	  Coulter,	  Brea,	  CA),	  quantified	  and	  80	  samples	  (75	  experimental	  
and	  5	  controls)	  were	  pooled	  together.	  Pooled	  libraries	  were	  sequenced	  on	  Hiseq	  
31	  
2500	  using	  paired-­‐end	  101	  base	  pair	  reads	  according	  to	  the	  manufacturers	  protocol.	  
Sequence	  reads	  were	  analyzed	  a	  processed	  using	  a	  modified	  version	  of	  the	  
bioinformatics	  pipeline	  and	  quality	  filters	  described	  above	  for	  whole-­‐exome	  
sequence	  analysis.	  Sequence	  run	  quality	  and	  analysis	  validity	  was	  assessed	  for	  each	  
pool	  via	  analysis	  of	  the	  control	  samples.	  The	  probe	  design	  was	  performed	  by	  
Victoria	  Clark.	  The	  MIPs	  protocol	  was	  performed	  by	  Jacob	  Baranoski.	  Pooled	  library	  
sequencing	  was	  performed	  by	  YCGA.	  The	  bioinformatics	  pipeline	  was	  modified	  and	  
sequence	  files	  were	  run	  by	  Victoria	  Clark.	  Sequence	  results	  were	  analyzed	  by	  Jacob	  





Coding	  variants	  detected	  by	  whole-­‐exome,	  custom	  amplicon,	  and	  MIPs	  sequencing	  
were	  confirmed	  by	  Sanger	  sequencing	  using	  standard	  protocols.	  An	  additional	  
cohort	  of	  tumors	  was	  also	  screened	  for	  mutations	  within	  the	  coding	  regions	  of	  the	  
SMARCB1	  gene	  via	  Sanger	  sequencing	  using	  standard	  protocols.	  Tumor-­‐matched	  
blood	  samples	  were	  also	  screened	  for	  mutations	  within	  the	  coding	  regions	  of	  the	  
SMARCB1	  gene	  via	  Sanger	  sequencing	  using	  standard	  protocols	  to	  establish	  that	  
mutations	  identified	  in	  tumor	  tissue	  were	  indeed	  somatic	  mutations.	  Briefly,	  
selected	  exons	  and	  selected	  exon–intron	  boundaries	  (based	  on	  whole-­‐exome	  and	  
MIPs	  sequence	  data)	  of	  SMARCB1	  were	  identified	  using	  the	  University	  of	  California,	  
Santa	  Cruz	  (UCSC)	  Genome	  Browser	  (http://genome.ucsc.edu).	  Unique	  primers	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were	  designed	  using	  Sequencher	  4.8	  (Gene	  Codes)	  and	  synthesized	  by	  the	  W.M.	  
Keck	  DNA	  Sequencing	  Facility	  at	  Yale	  School	  of	  Medicine.	  The	  selected	  fragments	  
were	  amplified,	  purified	  and	  direct	  re-­‐sequencing	  was	  performed	  using	  ABI’s	  9800	  
Fast	  Thermocyclers	  via	  polymerase	  chain	  reaction	  (PCR).	  The	  amplicons	  were	  
analyzed	  on	  a3730xL	  DNA	  Analyser	  (Applied	  Biosystems)	  at	  the	  W.M.	  Keck	  DNA	  
Sequencing	  Facility	  at	  Yale	  School	  of	  Medicine.	  Variants	  were	  identified	  using	  
Sequencher	  4.8	  (Gene	  Codes)	  by	  comparing	  the	  sequences	  obtained	  from	  the	  tumor	  
samples	  to	  the	  reference	  sequence	  as	  obtained	  from	  UCSC	  Genome	  Browser	  
(http://genome.ucsc.edu).	  Amplification	  and	  sequencing	  primers	  were	  designed	  by	  
Jacob	  Baranoski.	  PCRs	  and	  sample	  submission	  were	  preformed	  by	  Jacob	  Baranoski.	  
Sequencing	  were	  performed	  by	  the	  W.M.	  Keck	  DNA	  Sequencing	  Facility	  at	  Yale	  




Chromosome	  22	  Assessment	  via	  Q-­‐PCR	  	  
	  
Chromosome	  22	  status	  was	  assessed	  by	  quantitative	  real-­‐time	  PCR	  (Q-­‐PCR)	  using	  
Fast	  SYBR	  Green	  Master	  Mix	  (Roche	  Applied	  Science,	  Indianapolis,	  IN,	  USA).	  	  
For	  each	  sample,	  two	  exons	  (exon	  3	  and	  exon	  12)	  in	  the	  NF2	  gene	  were	  used	  for	  
quantification	  and	  normalized	  against	  primers	  for	  two	  or	  three	  control	  
chromosomes	  (a	  combination	  of	  Chr10,	  Chr11,	  and	  Chr16).	  Samples	  and	  controls	  
were	  run	  in	  triplicate.	  Dissociation-­‐curves	  were	  generated	  to	  ensure	  primer	  
33	  
specificity.	  To	  determine	  the	  threshold	  cycle,	  female	  reference	  DNA	  (Promega,	  
Madison,	  WI,	  USA),	  diluted	  at	  22ng/uL	  was	  used	  for	  4	  serial	  dilutions	  from	  1/4	  fold	  
to	  1/256.	  Each	  qPCR	  run	  were	  compared	  to	  3	  samples:	  a	  commercially	  available	  
reference	  female	  DNA,	  DNA	  from	  a	  whole	  genome	  genotyped	  meningioma	  sample	  
with	  known	  Chr22	  loss,	  and	  DNA	  from	  a	  whole	  genome	  genotyped	  meningioma	  
sample	  with	  known	  intact	  Chr22.	  A	  ratio	  <	  0.7	  was	  used	  as	  criteria	  for	  determining	  






An	  alternative	  method	  that	  was	  also	  used	  to	  assess	  chromosome	  22	  status,	  as	  well	  
as	  the	  integrity	  of	  the	  twenty-­‐two	  other	  chromosomes,	  was	  whole-­‐genome	  
genotyping	  analysis.	  To	  accomplish	  this,	  the	  Illumina	  Platform	  was	  utilized.	  Human	  
OmniExpress-­‐12v1.0	  BeadChips	  were	  used	  according	  to	  the	  manufacturer’s	  
protocol	  (Illumina,	  San	  Diego,	  CA,	  USA).	  Copy	  number	  variations	  (CNVs)	  were	  
detected	  by	  comparing	  the	  normalized	  signal	  intensity	  between	  tumor	  and	  matched	  
blood	  or	  tumor	  and	  the	  average	  of	  all	  blood	  samples	  if	  specific	  patient	  matched	  
blood	  was	  not	  available	  or	  not	  genotyped.	  Segmentation	  was	  performed	  on	  log	  
intensity	  ratios	  using	  DNACopy	  algorithm	  (201).	  Large-­‐scale	  chromosomal	  deletion	  
or	  amplification	  was	  defined	  as	  affecting	  more	  than	  one-­‐third	  of	  the	  chromosomal	  
arm	  with	  accompanying	  log	  ratio	  of	  signal	  intensities	  <	  -­‐0.1	  or	  >	  0.1,	  and	  B	  allele	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frequencies	  (BAF)	  at	  heterozygous	  sites	  deviating	  from	  0.5	  by	  at	  least	  0.05	  units.	  
Large-­‐scale	  copy	  neutral	  LOH	  was	  defined	  similarly,	  with	  the	  exception	  of	  log	  ratio	  
of	  signal	  intensities	  being	  between	  -­‐0.1	  and	  0.1.	  Sample	  preparation	  was	  performed	  
by	  Jacob	  Baranoski	  and	  Victoria	  Clark.	  Genotyping	  chips	  were	  sequenced	  by	  YCGA.	  
Log	  intensity	  ratios	  were	  calculated	  by	  Akdes	  Serrin.	  Result	  analyses	  were	  
performed	  by	  Akdes	  Serrin,	  Jacob	  Baranoski,	  and	  Victoria	  Clark.	  
	  
	  
RNA	  Expression	  Analysis	  	  
	  
To	  determine	  the	  levels	  of	  relative	  gene	  expression	  in	  tumor	  samples,	  Illumina	  
HumanHT12.v4	  gene	  expression	  microarray	  chips	  were	  used.	  RNA	  Integrity	  
Number	  (RIN)	  analysis	  was	  first	  performed	  to	  ensure	  adequate	  RNA	  quality.	  
Extracted	  tumor	  RNA	  samples	  were	  placed	  on	  Agilent	  RNA	  Nano	  Chips	  (Agilent	  
Technologies,	  Santa	  Clara,	  CA).	  These	  samples	  were	  then	  analyzed	  on	  Agilent	  2100	  
Bioanalyzer	  using	  the	  manufacture’s	  protocol	  and	  software	  (Agilent	  Technologies,	  
Santa	  Clara,	  CA).	  Samples	  with	  RINs	  less	  than	  7	  were	  excluded	  from	  further	  analysis.	  
	  
Data	  from	  the	  Illumina	  HumanHT12.v4	  gene	  expression	  microarray	  chips	  for	  
samples	  that	  passed	  quality	  control	  metrics	  were	  used	  to	  perform	  an	  unsupervised	  
hierarchical	  clustering	  using	  the	  euclidean	  distance	  as	  the	  dissimilarity	  metric	  and	  
the	  average	  agglomerative	  method	  for	  clustering.	  Differential	  gene	  expression	  
analysis	  was	  then	  performed	  using	  the	  log-­‐odds	  of	  differential	  expression	  value	  as	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implemented	  in	  the	  ebayes	  method	  of	  the	  limma	  R	  package.	  Tumor	  samples	  were	  
compared	  to	  tumors	  with	  other	  driver	  mutations	  and	  also	  to	  normal	  adult	  and	  
embryologic	  meningeal	  tissue.	  RIN	  analysis	  was	  performed	  by	  Jacob	  Baranoski.	  
Sample	  preparation	  was	  performed	  by	  Jacob	  Baranoski	  and	  Victoria	  Clark.	  
Expression	  microarray	  protocol	  was	  performed	  by	  YCGA.	  Unsupervised	  hierarchical	  
clustering	  were	  performed	  by	  Akdes	  Serrin.	  Comparative	  analyses	  were	  performed	  
by	  Akdes	  Serrin	  and	  Jacob	  Baranoski.	  
	  




Identification	  of	  SMARCB1-­‐Mutant	  Meningiomas	  
	  
Whole-­‐Exome	  and	  Custom	  Amplicon	  Sequencing	  	  
	  
Whole-­‐exome	  sequencing	  performed	  on	  a	  discovery	  cohort	  of	  meningiomas	  (n=50)	  
identified	  two	  tumors	  with	  somatic	  SMARCB1	  mutations.	  The	  first	  tumor,	  designated	  
MUN-­‐MN-­‐301,	  harbored	  a	  point	  mutation	  in	  an	  exon	  of	  the	  SMARCB1	  gene	  (Chr22:	  
24176339;	  G>A),	  which	  resulted	  in	  a	  R386H	  amino	  acid	  substitution.	  The	  second	  
meningioma,	  MUN-­‐MN-­‐295,	  was	  identified	  to	  harbor	  a	  single	  base	  pair	  deletion	  
(Chr22:	  24175813del;	  AC>A),	  resulting	  in	  a	  frameshift	  mutation.	  Each	  of	  these	  
tumors	  was	  also	  found	  to	  possess	  a	  concurrent	  somatic	  mutation	  in	  the	  NF2	  gene.	  
MUN-­‐MN-­‐301	  possessed	  a	  single	  base	  pair	  insertion	  in	  the	  NF2	  gene	  (Chr22:	  
30032748ins;	  G>GA)	  resulting	  in	  a	  frameshift	  mutation.	  MUN-­‐MN-­‐295	  also	  
harbored	  a	  frameshift	  mutation	  in	  the	  NF2	  gene	  (Chr22:	  30035146del;	  
AGAATGCT>A).	  	  
	  
A	  replication	  cohort	  of	  meningiomas	  (n=262)	  was	  then	  analyzed	  via	  custom	  
amplicon	  sequencing.	  Amplicon	  sequencing	  identified	  an	  additional	  five	  
meningiomas	  with	  somatic	  SMARCB1	  mutations.	  Interestingly,	  four	  of	  these	  five	  
tumors	  were	  found	  to	  harbor	  the	  identical	  mutation	  as	  was	  discovered	  in	  MUN-­‐MN-­‐
301	  –	  R386H.	  The	  fifth	  tumor	  possessed	  a	  single	  base	  pair	  mutation	  resulting	  in	  an	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amino	  acid	  substitution	  at	  a	  neighboring	  location	  –	  R383Q.	  These	  data	  are	  
summarized	  in	  Table	  1.	  
	  
	  
Table	  1.	  SMARCB1	  Mutations	  Identified	  via	  Whole-­‐Exome	  and	  Custom	  





Method	   SMARCB1	  Mutation	  
SMARCB1	  Mutation	  
Consequence	  
MUN-­‐MN-­‐295	   Whole-­‐Exome	   Chr22:24175813_AC>A	   Frameshift	  
MUN-­‐MN-­‐301	   Whole-­‐Exome	   Chr22:24176339_G>A	   R386H	  
MSK-­‐MN-­‐500	   Amplicon	   Chr22:24176339_G>A	   R386H	  
MSK-­‐MN-­‐584	   Amplicon	   Chr22:24176330_G>A	   R383Q	  
MSK-­‐MN-­‐845-­‐1	   Amplicon	   Chr22:24176339_G>A	   R386H	  
MUN-­‐MN-­‐263	   Amplicon	   Chr22:24176339_G>A	   R386H	  
MUN-­‐MN-­‐56	   Amplicon	   Chr22:24176339_G>A	   R386H	  
	  
	  
Molecular	  Inversion	  Probe	  Sequencing	  
	  
The	  identification	  of	  SMARCB1	  mutations	  via	  whole-­‐exome	  and	  amplicon	  
sequencing	  prompted	  further	  investigation	  of	  this	  gene	  in	  meningiomas.	  Molecular	  
inversion	  probes	  (MIPs)	  were	  designed	  to	  analyze	  the	  coding	  regions	  of	  the	  
SMARCB1	  and	  NF2	  genes	  (as	  well	  as	  TRAF7,	  KLF4,	  AKT1,	  and	  SMO)	  based	  on	  the	  
whole-­‐exome	  sequencing	  results.	  A	  cohort	  of	  436	  previously	  unanalyzed	  
meningiomas	  of	  various	  grades	  and	  locations	  were	  sequenced	  using	  MIPs	  
sequencing.	  Seventeen	  of	  these	  meningiomas	  were	  identified	  as	  having	  SMARCB1	  
mutations.	  Thirteen	  of	  these	  17	  tumors	  harbored	  the	  R386H	  SMARCB1	  mutation	  
identified	  in	  the	  whole-­‐exome	  and	  amplicon	  sequenced	  cohorts;	  2	  were	  found	  to	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harbor	  the	  R383Q	  SMARCB1	  mutation	  identified	  in	  one	  of	  the	  amplicon	  sequenced	  
tumors;	  2	  were	  found	  to	  have	  frameshift	  mutations.	  Of	  these	  17	  meningiomas	  found	  
to	  harbor	  SMARCB1	  mutations,	  12	  were	  identified	  by	  MIPs	  sequencing	  to	  have	  
concurrent	  mutations	  affecting	  the	  coding	  region	  of	  NF2.	  In	  addition	  to	  these	  17	  
meningiomas,	  a	  single	  tumor	  (YALE-­‐1205)	  was	  identified	  to	  have	  a	  SMARCB1	  R386H	  










Method	   SMARCB1	  Mutation	  
SMARCB1	  Mutation	  
Consequence	  
BONN-­‐T-­‐1075	   MIPs	   Chr22:24176339_G>A	   R386H	  
BONN-­‐T-­‐1215	   MIPs	   Chr22:24176339_G>A	   R386H	  
BONN-­‐T-­‐1797	   MIPs	   Chr22:24176339_G>A	   R386H	  
BONN-­‐T-­‐2102	   MIPs	   Chr22:24176339_G>A	   R386H	  
BONN-­‐T-­‐2108	   MIPs	   Chr22:24176339_G>A	   R386H	  
BONN-­‐T-­‐2296	   MIPs	   Chr22:24176339_G>A	   R386H	  
BONN-­‐T-­‐2432	   MIPs	   Chr22:24176339_G>A	   R386H	  
BONN-­‐T-­‐2758	   MIPs	   Chr22:24176339_G>A	   R386H	  
BONN-­‐T-­‐314	   MIPs	   Chr22:24176330_G>A	   R383Q	  
BONN-­‐T-­‐3991	   MIPs	   Chr22:24176330_G>A	   R383Q	  
BONN-­‐T-­‐4136	   MIPs	   Chr22:24176339_G>A	   R386H	  
BONN-­‐T-­‐439	   MIPs	   Chr22:24176339_G>A	   R386H	  
BONN-­‐T-­‐841	   MIPs	   Chr22:24176339_G>A	   R386H	  
BONN-­‐T-­‐847	   MIPs	   Chr22:24175835_ACT>A	   Frameshift	  
KOLN-­‐HT-­‐2835	   MIPs	   Chr22:24175835_ACT>A	   Frameshift	  
KOLN-­‐HT-­‐3369	   MIPs	   Chr22:24176339_G>A	   R386H	  
YALE-­‐251	   MIPs	   Chr22:24176339_G>A	   R386H	  
BONN-­‐T-­‐1205	  
Sanger	  
Screening	   Chr22:24176339_G>A	   R386H	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Sanger	  Confirmations	  of	  SMARCB1	  Mutations	  and	  Verification	  as	  Somatic	  Variants	  
	  
The	  24	  meningiomas	  identified	  as	  being	  SMARCB1-­‐mutant	  via	  whole-­‐exome,	  
amplicon,	  and	  MIPs	  sequencing	  underwent	  subsequent	  Sanger	  sequencing	  to	  
confirm	  the	  called	  SMARCB1	  variants.	  All	  24	  variants	  were	  successfully	  confirmed	  
via	  Sanger	  sequencing.	  Figure	  2a	  is	  a	  representative	  chromatogram	  demonstrating	  
Sanger	  sequencing	  confirmation	  of	  a	  heterozygous	  SMARCB1	  mutation	  in	  



















Figure	  2.	  SMARCB1-­‐Mutant	  Meningiomas	  Harbor	  Somatic	  SMARCB1	  Mutations	  in	  an	  NF2-­‐
Mutant	  Background	  
	  
A.)	  Representative	  chromatogram	  demonstrating	  Sanger	  confirmation	  of	  the	  heterozygous	  SMARCB1	  
R386H	  variant	  in	  the	  tumor	  tissue	  from	  subject	  YALE-­‐251.	  Similar	  chromatograms	  were	  obtained	  for	  
the	  other	  23	  meningiomas	  identified	  as	  being	  SMARCB1-­‐mutant	  via	  whole-­‐exome,	  custom	  amplicon,	  
and	  MIPs	  sequencing	  –	  all	  identified	  SMARCB1	  variants	  were	  successfully	  Sanger	  confirmed.	  
B.)	  Representative	  chromatogram	  demonstrating	  Sanger	  screening	  of	  the	  SMARCB1	  gene	  in	  the	  
germline	  DNA	  obtained	  from	  white	  blood	  cells	  for	  subject	  YALE-­‐251.	  Note	  that	  the	  G>A	  substitution	  
that	  results	  in	  the	  R386H	  variant	  that	  was	  present	  in	  the	  tumor	  tissue	  for	  subject	  YALE-­‐251	  is	  not	  
present	  in	  the	  germline	  DNA.	  This	  verified	  that	  SMARCB1	  mutation	  was	  a	  somatic	  mutation.	  Similar	  
chromatograms	  were	  obtained	  for	  the	  other	  9	  subjects	  for	  which	  germline	  DNA	  was	  available.	  All	  
SMARCB1	  variants	  screened	  were	  identified	  as	  somatic	  mutations.	  	  
C.)	  Representative	  results	  of	  NF2	  q-­‐PCR	  analysis	  for	  subject	  YALE-­‐251	  demonstrating	  NF2-­‐loss.	  Two	  
exons	  (3	  and	  12)	  of	  NF2	  were	  quantified	  relative	  to	  control	  exons	  on	  chromosomes	  11	  and	  16.	  A	  ratio	  
of	  <0.7	  was	  utilized	  as	  the	  cut	  off	  for	  deletion	  (ratio	  determined	  by	  pilot	  data	  utilizing	  whole-­‐genome	  
genotyping	  results).	  Similar	  results	  demonstrating	  NF2-­‐loss	  were	  obtained	  for	  the	  other	  SMARCB1-­‐
mutant	  tumors	  screened	  via	  q-­‐PCR.	  All	  25	  SMARCB1-­‐mutant	  meningiomas	  were	  found	  to	  harbor	  
concurrent	  mutations	  in	  NF2	  and/or	  concurrent	  NF2-­‐loss	  /	  Chr22-­‐loss.	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Subject	  blood	  samples	  were	  available	  for	  10	  of	  the	  25	  meningiomas	  identified	  
harboring	  SMARCB1	  mutations.	  DNA	  obtained	  from	  the	  white	  blood	  cells	  of	  these	  
patients	  underwent	  Sanger	  sequencing	  screening	  for	  the	  SMARCB1	  mutations	  
identified	  in	  the	  respective	  paired	  tumor	  samples.	  None	  of	  the	  SMARCB1	  mutations	  
identified	  in	  the	  tumor	  samples	  were	  present	  in	  the	  DNA	  obtained	  from	  the	  
respective	  patient’s	  white	  blood	  cells,	  indicating	  that	  the	  SMARCB1	  variants	  present	  
in	  the	  meningiomas	  are	  indeed	  somatic	  mutations.	  See	  Figure	  2b.	  These	  data	  are	  
summarized	  in	  Table	  3.	  
	  
	  




SMARCB1	  Mutation	  in	  
Tumor	  
SMARCB1	  Gene	  
Status	  in	  Subject's	  
Germline	  DNA	  
BONN-­‐T-­‐1797	   R386H	   Wildtype	  
BONN-­‐T-­‐2758	   R386H	   Wildtype	  
BONN-­‐T-­‐314	   R383Q	   Wildtype	  
BONN-­‐T-­‐439	   R386H	   Wildtype	  
BONN-­‐T-­‐841	   R386H	   Wildtype	  
MSK-­‐MN-­‐584	   R383Q	   Wildtype	  
MSK-­‐MN-­‐845-­‐1	   R386H	   Wildtype	  
MUN-­‐MN-­‐295	   Frameshift	  
(Chr22:24175813_AC>A)	  
Wildtype	  
MUN-­‐MN-­‐301	   R386H	   Wildtype	  






SMARCB1-­‐Mutant	  Meningiomas	  Represent	  a	  Distinct	  Subset	  of	  NF2-­‐Mutant	  
Meningiomas	  
	  
Somatic	  SMARCB1	  Mutations	  with	  Concurrent	  NF2	  Mutations	  and/or	  Chr22	  Loss	  
	  
In	  addition	  to	  identifying	  SMARCB1	  mutations,	  whole-­‐exome,	  custom	  amplicon,	  and	  
MIPs	  sequencing	  technologies	  were	  used	  to	  identify	  coding	  mutations	  affecting	  the	  
NF2	  gene.	  Likewise,	  whole-­‐genome	  genotyping	  and	  Q-­‐PCR	  analyses	  were	  conducted	  
to	  identify	  chromosome	  22	  (Chr22)	  and	  NF2	  gene	  deletion,	  respectively.	  	  
	  
As	  in	  the	  two	  tumors	  that	  had	  SMARCB1	  mutations	  identified	  via	  whole-­‐exome	  
sequencing,	  all	  five	  of	  the	  SMARCB1-­‐mutant	  tumors	  identified	  via	  amplicon	  
sequencing	  were	  also	  found	  to	  possess	  concurrent	  mutations	  in	  NF2	  and/or	  
concurrent	  NF2-­‐loss	  /	  Chr22-­‐loss	  (determined	  via	  genotyping	  and/or	  NF2	  Q-­‐PCR	  
analyses).	  
	  
Similarly,	  all	  17	  SMARCB1-­‐mutant	  meningiomas	  identified	  via	  MIPs	  sequencing	  and	  
the	  one	  SMARCB1-­‐mutant	  tumor	  identified	  via	  Sanger	  screening	  were	  also	  found	  to	  
possess	  concurrent	  mutations	  in	  NF2	  and/or	  concurrent	  deletion	  of	  Chr22	  or	  NF2	  
(determined	  via	  genotyping	  and/or	  NF2	  Q-­‐PCR	  analyses).	  See	  Figure	  2c.	  These	  data	  










Method	   SMARCB1	  Mutation	   NF2	  Status	   NF2	  Mutation	  
BONN-­‐T-­‐1075	   MIPs	   R386H	   NF2-­‐mutant	   Chr22:30032805_G>A	  
BONN-­‐T-­‐1205	   Sanger	  
Screening	  
R386H	   NF2-­‐loss	   n/a	  
BONN-­‐T-­‐1215	   MIPs	   R386H	   Chr22q-­‐loss	   n/a	  
BONN-­‐T-­‐1797	   MIPs	   R386H	   NF2-­‐mutant	   Chr22:30051666_G>T	  
BONN-­‐T-­‐2102	   MIPs	   R386H	   NF2-­‐loss	  &	  
NF2-­‐mutant	  
Chr22:30038219_TC>T	  
BONN-­‐T-­‐2108	   MIPs	   R386H	   NF2-­‐loss	  &	  
NF2-­‐mutant	  
Chr22:30032794_C>T	  
BONN-­‐T-­‐2296	   MIPs	   R386H	   Chr22q-­‐loss	   n/a	  
BONN-­‐T-­‐2432	   MIPs	   R386H	   NF2-­‐mutant	   Chr22:30057330_T>C	  
BONN-­‐T-­‐2758	   MIPs	   R386H	   NF2-­‐mutant	   Chr22:30035201_G>C	  ;	  
Chr22:30067867_G>A	  




BONN-­‐T-­‐3991	   MIPs	   R383Q	   Chr22q-­‐loss	   n/a	  




BONN-­‐T-­‐439	   MIPs	   R386H	   NF2-­‐mutant	   Chr22:30057326_GA>G	  
BONN-­‐T-­‐841	   MIPs	   R386H	   Chr22q-­‐loss	   n/a	  
BONN-­‐T-­‐847	   MIPs	   Frameshift	  
(Chr22:24175835_ACT>A)	  
NF2-­‐mutant	   Chr22:30057329_G>A	  
KOLN-­‐HT-­‐2835	   MIPs	   Frameshift	  
(Chr22:24175835_ACT>A)	  
NF2-­‐mutant	   Chr22:30051639_G>A	  
KOLN-­‐HT-­‐3369	   MIPs	   R386H	   NF2-­‐mutant	   Chr22:30032854_ATGGA>A	  
MSK-­‐MN-­‐500	   Amplicon	   R386H	   NF2-­‐loss	  &	  
NF2-­‐mutant	  
Chr22:30067836_C>T	  
MSK-­‐MN-­‐584	   Amplicon	   R383Q	   NF2-­‐loss	  &	  
NF2-­‐mutant	  
Chr22:30057302_C>T	  
MSK-­‐MN-­‐845-­‐1	   Amplicon	   R386H	   NF2-­‐loss	  &	  
NF2-­‐mutant	  
Chr22:30051639_G>A	  





Chr22q-­‐loss	   n/a	  
MUN-­‐MN-­‐301	   Whole-­‐
Exome	  
R386H	   Chr22q-­‐loss	   n/a	  
MUN-­‐MN-­‐56	   Amplicon	   R386H	   Chr22q-­‐loss	   n/a	  




Whole-­‐genome	  genotyping	  was	  also	  used	  to	  assess	  the	  stability	  of	  all	  23	  
chromosomes	  for	  some	  of	  these	  tumors.	  The	  genomes	  of	  the	  SMARCB1-­‐mutant	  
meningiomas	  appear	  relatively	  stable.	  Only	  2	  of	  the	  10	  tumors	  that	  underwent	  
whole-­‐genome	  genotyping	  analysis	  demonstrated	  any	  large-­‐scale	  chromosomal	  
events	  aside	  from	  chromosome	  22q	  loss.	  When	  examining	  the	  chromosomal	  
stability	  of	  4	  high-­‐grade	  SMARCB1-­‐mutant	  meningiomas	  analyzed,	  only	  one	  had	  any	  
large-­‐scale	  events	  aside	  from	  chromosome	  22q	  loss.	  These	  data	  are	  summarized	  in	  
Table	  5.	  Interestingly,	  this	  stability	  is	  in	  contrast	  to	  the	  usual	  finding	  of	  widespread	  
chromosomal	  instability	  in	  high-­‐grade	  tumors.	  For	  example,	  24	  of	  26	  non-­‐SMARCB1-­‐
mutant	  NF2-­‐mutant	  /	  Chr22-­‐loss	  high-­‐grade	  meningiomas	  in	  our	  database	  had	  
large-­‐scale	  chromosomal	  alterations	  (and/or	  numerous	  focal	  events)	  in	  addition	  to	  
Chr22q	  loss.	  These	  data	  are	  summarized	  in	  Appendix	  Table	  1.	  
	  
	  



























Focal	  Chr	  LOH	  
Events	  
BONN-­‐T-­‐1215	   R386H	   1	   8p	  /	  8q	  /	  22q	   None	   None	   None	   None	   None	  
BONN-­‐T-­‐2296	   R386H	   1	   22q	   16p	  /	  19p	   None	   None	   None	   None	  
BONN-­‐T-­‐314	   R383Q	   2	   22q	   None	   None	   None	   None	   None	  
BONN-­‐T-­‐3991	   R383Q	   1	   22q	   19p	   None	   None	   None	   None	  
BONN-­‐T-­‐4136	   R386H	   1	   22q	   None	   None	   None	   None	   None	  
BONN-­‐T-­‐841	   R386H	   2	   22q	   None	   None	   None	   None	   None	  
KOLN-­‐HT-­‐2835	   Frameshift	   2	   22q	   None	   None	   None	   None	   None	  
MUN-­‐MN-­‐295	   Frameshift	   2	   22q	   None	   8p	   None	   None	   None	  
MUN-­‐MN-­‐301	   R386H	   1	   22q	   None	   None	   None	   None	   None	  
MUN-­‐MN-­‐56	   R386H	   1	   22q	   16p	  /	  20q	   None	   None	   None	   3p	  /	  12p	  /	  12q	  
	  
Chr	  =	  Chromosomal	  	  	  	  	  	  	  	  	  	  Amp.	  =	  Amplification	  	  	  	  	  	  	  	  	  	  LOH	  =	  Loss	  of	  heterozygosity	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Expression	  Profile	  of	  SMARCB1-­‐Mutant	  Meningiomas	  	  
	  
To	  further	  characterize	  these	  SMARCB1-­‐mutant	  meningiomas,	  we	  performed	  gene	  
expression	  analysis.	  Unsupervised	  hierarchical	  clustering	  analysis	  based	  on	  
meningioma	  gene	  expression	  data	  demonstrated	  that	  the	  expression	  profiles	  of	  
SMARCB1-­‐mutant	  meningiomas	  cluster	  similarly	  to	  other	  NF2-­‐mutant/Chr22	  loss	  
meningiomas.	  That	  is,	  the	  expression	  profiles	  of	  these	  tumors	  are	  distinctly	  different	  
from	  the	  expression	  profiles	  of	  meningiomas	  that	  do	  not	  harbor	  concurrent	  NF2	  
mutations	  (TRAF7/AKT1-­‐mutant	  meningiomas,	  for	  example).	  However,	  within	  this	  




















Figure	  3.	  Unsupervised	  Hierarchal	  Clustering	  Analysis	  of	  Meningioma	  Gene	  Expression	  
Unsupervised	  hierarchal	  clustering	  results	  of	  gene	  expression	  analysis	  for	  meningiomas.	  Each	  
terminal	  branch	  of	  the	  graph	  (and	  associated	  bar)	  represents	  a	  single	  tissue	  sample.	  The	  more	  closely	  
clustered	  the	  terminal	  branches,	  the	  more	  similar	  the	  samples	  are;	  expression	  profiles	  of	  tissues	  that	  
are	  dissimilar	  have	  branches	  further	  apart.	  Each	  color	  bar	  represents	  a	  different	  tissue	  type	  –	  red	  is	  
SMARCB1-­‐mutant	  meningiomas;	  blue	  is	  non-­‐SMARCB1-­‐mutant	  NF2-­‐mutant	  meningiomas;	  yellow	  is	  
non-­‐SMARCB1,	  non-­‐NF2	  mutant	  meningiomas;	  green	  is	  normal	  adult	  meningeal	  control	  tissue.	  	  
Meningiomas,	  as	  a	  whole,	  demonstrate	  a	  very	  distinct	  gene	  expression	  profile	  from	  that	  of	  normal	  
adult	  meningeal	  tissue	  (as	  evident	  by	  the	  divergent	  branching	  pattern	  at	  the	  earliest	  point	  in	  the	  
tree).	  Within	  the	  meningiomas,	  NF2-­‐mutant	  and	  non-­‐NF2	  mutant	  meningiomas	  exhibit	  very	  distinct	  
expression	  profiles.	  Within	  the	  NF2-­‐mutant	  meningioma	  superfamily,	  note	  that	  SMARCB1-­‐mutant	  
tumors	  appear	  to	  form	  a	  unique	  subgroup	  that	  is	  distinct	  from	  the	  majority	  of	  non-­‐SMARCB1-­‐mutant	  










Increased	  Expression	  of	  GLI1	  and	  EZH2	  Contribute	  to	  Differential	  Clustering	  of	  
SMARCB1-­‐Mutant	  Meningiomas	  within	  the	  NF2-­‐Mutant	  Meningioma	  Superfamily	  
	  
To	  investigate	  the	  factors	  that	  account	  for	  this	  distinct	  clustering	  within	  the	  NF2	  
superfamily,	  we	  performed	  differential	  gene	  expression	  analysis.	  We	  sought	  to	  
determine	  which	  genes	  were	  either	  more	  or	  less	  expressed	  in	  these	  SMARCB1-­‐
mutant	  meningiomas	  compared	  to	  other	  NF2-­‐mutant	  (but	  non-­‐SMARCB1-­‐mutant)	  
meningiomas,	  non-­‐NF2-­‐mutant	  meningiomas,	  and	  normal	  adult	  meningeal	  tissue	  as	  
a	  control.	  	  
	  
The	  top	  two	  differentially	  over-­‐expressed	  genes	  in	  SMARCB1-­‐mutant	  meningiomas	  
compared	  to	  non-­‐SMARCB1-­‐mutant	  NF2-­‐mutant	  meningiomas	  were	  SCG2	  and	  
RSPO3.	  	  
	  
SCG2	  codes	  for	  the	  protein	  secretogranin	  II.	  Secretogranin	  II	  is	  thought	  be	  involved	  
in	  the	  packaging	  of	  neuropeptides	  into	  secretory	  vesicles	  (202,	  203).	  Secretogranin	  
II	  can	  be	  cleaved	  to	  an	  active	  form	  called	  Secretoneurin	  (204).	  Previous	  studies	  have	  
found	  increased	  SCG2	  expression	  in	  other	  tumor	  types	  (205)	  and	  secretogranin	  II	  
has	  also	  been	  shown	  to	  inhibit	  apoptosis	  by	  blocking	  caspase-­‐3	  activation	  (206).	  
SCG2	  expression	  in	  SMARCB1-­‐mutant	  meningiomas	  was	  also	  increased	  when	  
compared	  to	  SCG2	  expression	  levels	  in	  normal	  control	  meningeal	  tissue.	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RSPO3	  codes	  for	  the	  protein	  R-­‐spondin	  3,	  which	  is	  a	  secreted	  protein	  known	  to	  
regulate	  beta-­‐catenin	  (CTNNB1)	  (207).	  RSPO3	  fusions	  have	  been	  previously	  
associated	  with	  a	  subset	  of	  colon	  cancer	  (208)	  and	  increased	  RSPO3	  expression	  has	  
been	  demonstrated	  in	  other	  cancer	  types	  (209).	  RSPO3	  expression	  in	  SMARCB1-­‐
mutant	  meningiomas	  was	  also	  found	  to	  be	  increased	  when	  compared	  to	  RSPO3	  
expression	  levels	  in	  normal	  control	  meningeal	  tissue.	  	  
	  
The	  top	  differentially	  under-­‐expressed	  gene	  that	  has	  previously	  been	  associated	  
with	  tumorigenesis	  in	  SMARCB1-­‐mutant	  meningiomas	  compared	  to	  non-­‐SMARCB1-­‐
mutant	  NF2-­‐mutant	  meningiomas	  was	  IGFBP3.	  IGFBP3	  codes	  for	  the	  protein	  Insulin-­‐
like	  growth	  factor-­‐binding	  protein	  3	  (IGFBP-­‐3).	  IGFBP-­‐3	  is	  capable	  of	  binding	  IGF-­‐1	  
and	  IGF-­‐2	  and	  preventing	  these	  ligands	  from	  binding	  to	  their	  receptor	  IGF1R	  (210,	  
211).	  IGFBP3	  is	  also	  considered	  to	  be	  a	  tumor	  suppressor	  gene;	  down-­‐regulation	  of	  
IGFBP3	  has	  previously	  been	  associated	  with	  numerous	  tumor	  types	  (212-­‐214).	  
IGFBP3	  expression	  in	  SMARCB1-­‐mutant	  meningiomas	  was	  also	  decreased	  when	  
compared	  to	  IGFBP3	  expression	  levels	  in	  normal	  control	  meningeal	  tissue.	  	  
	  
We	  next	  examined	  the	  relative	  expression	  levels	  of	  genes	  known	  to	  interact	  with	  
SMARCB1	  and	  be	  involved	  in	  tumorigenesis.	  These	  genes	  included	  MYC,	  CDKN2A,	  
CCND1,	  GLI1,	  and	  EZH2.	  	  
	  
Consistent	  with	  the	  previously	  reported	  interactions	  between	  SMARCB1	  and	  MYC,	  
MYC	  expression	  was	  decreased	  in	  SMARCB1-­‐mutant	  meningiomas	  compared	  to	  non-­‐
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SMARCB1-­‐mutant	  NF2-­‐mutant	  meningiomas.	  Interestingly,	  however,	  MYC	  
expression	  in	  SMARCB1-­‐mutant	  meningiomas	  was	  not	  decreased	  when	  compared	  to	  
MYC	  expression	  levels	  in	  normal	  control	  meningeal	  tissue.	  	  
	  
Similarly,	  consistent	  with	  the	  previously	  reported	  interactions	  between	  SMARCB1	  
and	  CDKN2A,	  CDKN2A	  expression	  was	  decreased	  in	  SMARCB1-­‐mutant	  meningiomas	  
compared	  to	  non-­‐SMARCB1-­‐mutant	  NF2-­‐mutant	  meningiomas.	  Again,	  however,	  
CDKN2A	  expression	  in	  SMARCB1-­‐mutant	  meningiomas	  was	  not	  decreased	  when	  
compared	  to	  CDKN2A	  expression	  levels	  in	  normal	  control	  meningeal	  tissue.	  	  
	  
CCND1	  levels	  were	  not	  directly	  assessed,	  however,	  the	  expression	  of	  other	  members	  
of	  the	  cyclin-­‐D	  family	  (CCND2	  and	  CCND3)	  were	  analyzed.	  Both	  CCND2	  and	  CCND3	  
expression	  levels	  were	  increased	  in	  SMARCB1-­‐mutant	  meningiomas	  compared	  to	  
non-­‐SMARCB1-­‐mutant	  NF2-­‐mutant	  meningiomas	  –	  this	  is	  what	  would	  be	  expected	  
for	  CCND1	  based	  on	  previously	  reported	  interactions	  between	  SMARCB1	  and	  CCND1.	  
Both	  CCND2	  and	  CCND3	  expression	  levels	  were	  also	  increased	  in	  SMARCB1-­‐mutant	  
meningiomas	  when	  compared	  to	  CCND2	  and	  CCND3	  expression	  levels	  in	  normal	  
control	  meningeal	  tissue.	  	  
	  
The	  next	  gene	  analyzed	  was	  GLI1,	  a	  member	  of	  the	  sonic	  hedgehog	  pathway.	  GLI1	  
expression	  was	  markedly	  increased	  in	  SMARCB1-­‐mutant	  meningiomas	  compared	  to	  
other	  NF2-­‐mutant	  meningiomas	  that	  did	  not	  harbor	  concurrent	  SMARCB1	  
mutations.	  Interestingly,	  the	  GLI1	  expression	  profile	  of	  these	  SMARCB1-­‐mutant	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meningiomas	  more	  closely	  resembled	  that	  of	  SMO-­‐mutant	  meningiomas	  that	  were	  
previously	  described	  by	  Clark	  et	  al.	  as	  tumors	  of	  the	  midline	  anterior	  skull	  base.	  
GLI1	  expression	  in	  SMARCB1-­‐mutant	  meningiomas	  was	  also	  increased	  when	  
compared	  to	  GLI1	  expression	  levels	  in	  normal	  control	  meningeal	  tissue.	  	  
	  
The	  final	  gene	  analyzed	  was	  EZH2,	  which	  codes	  for	  a	  member	  of	  the	  Polycomb-­‐
group	  protein	  family	  and	  is	  involved	  in	  chromatin	  remodeling.	  EZH2	  expression	  was	  
increased	  in	  SMARCB1-­‐mutant	  meningiomas	  compared	  to	  other	  NF2-­‐mutant	  
meningiomas	  that	  did	  not	  harbor	  concurrent	  SMARCB1	  mutations.	  EZH2	  expression	  
in	  SMARCB1-­‐mutant	  meningiomas	  was	  also	  increased	  when	  compared	  to	  EZH2	  
expression	  levels	  in	  normal	  control	  meningeal	  tissue.	  Expression	  data	  are	  
summarized	  in	  Table	  6.	  	  
	  






























SCG2	   10.529	   8.097	   5.854	   2.432	   4.675	  
RSPO3	   9.684	   7.328	   4.593	   2.356	   5.091	  
IGFBP3	   7.323	   8.869	   11.905	   -­‐1.546	   -­‐4.582	  
MYC	   7.577	   7.878	   5.479	   -­‐0.301	   2.098	  
CDKN2A	   4.978	   5.189	   4.778	   -­‐0.212	   0.200	  
CCND2	   9.170	   8.874	   8.860	   0.296	   0.310	  
CCND3	   10.243	   9.890	   9.639	   0.353	   0.605	  
GLI1	   6.169	   5.329	   4.775	   0.840	   1.394	  




The	  differential	  expression	  of	  these	  genes	  contributes	  to	  the	  distinct	  clustering	  of	  
the	  SMARCB1-­‐mutant	  meningiomas	  within	  the	  NF2-­‐mutant	  superfamily.	  A	  list	  of	  the	  
top	  300	  differentially	  expressed	  (top	  150	  up-­‐regulated	  and	  top	  150	  down-­‐
regulated)	  genes	  between	  SMARCB1-­‐mutant	  and	  non-­‐SMARCB1-­‐mutant	  NF2-­‐mutant	  
meningiomas	  are	  listed	  in	  Appendix	  Table	  2.	  	  
	  
	  
SMARCB1-­‐Mutant	  Meningiomas	  Are	  Midline	  Convexity	  Tumors	  with	  an	  
Increased	  Predilection	  to	  Be	  De	  Novo	  High-­‐Grade	  Lesions	  
	  
We	  sought	  to	  determine	  if	  the	  genomic	  differences	  identified	  in	  SMARCB1-­‐mutant	  
meningiomas	  correlated	  with	  distinctions	  in	  clinical	  presentation.	  Demographic	  and	  
clinical	  data	  for	  these	  patients	  are	  summarized	  in	  Table	  7.	  Of	  the	  25	  patients	  with	  
meningiomas	  20	  were	  female	  (80%).	  The	  median	  age	  at	  time	  of	  surgery	  was	  64	  
years.	  Among	  these	  25	  meningiomas,	  no	  specific	  low-­‐grade	  histological	  subtype	  was	  

































BONN-­‐T-­‐1075	   R386H	   51	   F	   1	   Transitional	   Convexity	   Frontal	   Non-­‐midline	  
BONN-­‐T-­‐1205	   R386H	   73	   F	   1	   Transitional	   ASB	   Olfactory	  Groove	   Midline	  
BONN-­‐T-­‐1215	   R386H	   75	   F	   1	   Transitional	   ASB	   Frontobasal	   Midline	  
BONN-­‐T-­‐1797	   R386H	   64	   F	   1	   Fibrous	   Spinal	   T2	   n/a	  
BONN-­‐T-­‐2102	   R386H	   56	   F	   1	   Transitional	   Convexity	   Parafalcine	   Midline	  
BONN-­‐T-­‐2108	   R386H	   73	   F	   1	   Transitional	   Convexity	   Parasagittal	   Midline	  
BONN-­‐T-­‐2296	   R386H	   68	   F	   1	   Psammomatous	   ASB	   Frontobasal	   Midline	  
BONN-­‐T-­‐2432	   R386H	   61	   F	   1	   Meningothelial	   Convexity	   Parasagittal	   Midline	  
BONN-­‐T-­‐2758	   R386H	   65	   M	   2	   Meningothelial	   Other	   Petrous	  Bone	   Lateral	  
BONN-­‐T-­‐314	   R383Q	   49	   F	   2	   Fibrous	   Convexity	   Parasagittal	   Midline	  
BONN-­‐T-­‐3991	   R383Q	   66	   F	   1	   Transitional	   Convexity	   Parafalcine	   Midline	  
BONN-­‐T-­‐4136	   R386H	   61	   F	   1	   Fibrous	   Convexity	   Parafalcine	   Midline	  
BONN-­‐T-­‐439	   R386H	   72	   M	   2	   Atypical	   Convexity	   Tentorial	   Non-­‐midline	  
BONN-­‐T-­‐841	   R386H	   67	   M	   2	   Atypical	   Convexity	   Parafalcine	   Midline	  
BONN-­‐T-­‐847	   Frameshift	   59	   F	   2	   Atypical	   Convexity	   Parafalcine	   Midline	  
KOLN-­‐HT-­‐2835	   Frameshift	   73	   M	   2	   n/a	   ASB	   Olfactory	  Groove	   Midline	  
KOLN-­‐HT-­‐3369	   R386H	   61	   M	   1	   Meningothelial	   ASB	   Olfactory	  Groove	   Midline	  
MSK-­‐MN-­‐500	   R386H	   64	   F	   2	   Atypical	   Convexity	   Frontal	   Non-­‐midline	  
MSK-­‐MN-­‐584	   R383Q	   54	   F	   1	   n/a	   Convexity	   Parafalcine	   Midline	  





MUN-­‐MN-­‐263	   R386H	   58	   F	   1	   LPMR	   Convexity	   Parasagittal	   Midline	  
MUN-­‐MN-­‐295	   Frameshift	   70	   F	   2	   atypical	   Convexity	   General	   Non-­‐midline	  
MUN-­‐MN-­‐301	   R386H	   58	   F	   1	   Psammomatous	   Convexity	   Parafalcine	   Midline	  
MUN-­‐MN-­‐56	   R386H	   51	   F	   1	   Transitional	   CPA	   CPA	   Lateral	  
YALE-­‐251	   R386H	   29	   F	   2	   n/a	   Convexity	   Parafalcine	   Midline	  
	  
Patient	  age	  is	  in	  years	   LPMR	  =	  Lymphoplasmacyte-­‐rich	  
ASB	  =	  anterior	  skull	  base	   MSB	  =	  middle	  skull	  base	  
CPA	  =	  cerebellopontine	  angle	   T2	  =	  2nd	  thoracic	  vertebrae	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Interestingly,	  SMARCB1-­‐mutant	  meningiomas	  appeared	  to	  have	  a	  slight	  predilection	  
to	  being	  high-­‐grade	  at	  time	  of	  surgery.	  Nine	  of	  the	  25	  (36%)	  were	  diagnosed	  as	  de	  
novo	  high-­‐grade	  lesions.	  This	  is	  a	  markedly	  higher	  percentage	  than	  reported	  in	  the	  
literature	  (~20%)	  (5-­‐7).	  Further,	  as	  noted	  above,	  these	  high-­‐grade	  SMARCB1-­‐
mutant	  meningiomas	  appear	  to	  possess	  markedly	  increased	  chromosomal	  stability	  
compared	  to	  non-­‐SMARCB1-­‐mutant	  NF2-­‐mutant	  high-­‐grade	  meningiomas.	  Neither	  
median	  patient	  age	  at	  time	  of	  surgery	  nor	  gender	  predominance	  for	  high-­‐grade	  
SMARCB1-­‐mutant	  meningiomas	  (65	  years;	  55%	  female)	  differed	  significantly	  from	  
those	  of	  non-­‐SMARCB1-­‐mutant	  NF2-­‐mutant	  high-­‐grade	  meningiomas	  (62	  years;	  
54%	  female).	  These	  data	  are	  summarized	  in	  Appendix	  Table	  3.	  
	  
We	  sought	  to	  identify	  a	  “mutation	  map”	  for	  SMARCB1-­‐mutant	  meningiomas.	  Lesion	  
location	  information	  was	  available	  for	  all	  25	  SMARCB1-­‐mutant	  meningiomas.	  24	  of	  
these	  25	  (96%)	  meningiomas	  were	  intracranial	  tumors;	  one	  was	  a	  spinal	  
meningioma	  occurring	  at	  level	  T2.	  Of	  the	  24	  intracranial	  tumors,	  16	  (67%)	  were	  
convexity	  lesions	  and	  5	  (21%)	  were	  anterior	  skull	  base	  meningiomas.	  	  
	  
Interestingly,	  when	  examining	  the	  intracranial	  convexity	  meningiomas,	  12	  of	  the	  16	  
(75%)	  were	  midline	  tumors	  –	  8	  parafalcine	  and	  4	  parasagittal.	  Similarly,	  when	  
looking	  at	  the	  SMARCB1-­‐mutant	  meningiomas	  that	  formed	  along	  the	  anterior	  skull	  
base,	  all	  5	  tumors	  (100%)	  were	  midline	  –	  3	  formed	  along	  the	  olfactory	  groove	  and	  2	  
were	  described	  as	  frontobasal	  lesions.	  Overall,	  of	  the	  24	  known	  intracranial	  
meningiomas,	  17	  (71%)	  originated	  along	  the	  midline.	  See	  Figure	  4.	  Taken	  together,	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these	  data	  suggest	  that	  SMARCB1-­‐mutant	  meningiomas	  are	  predominantly	  midline	  





Figure	  4.	  SMARCB1-­‐Mutant	  Meningiomas	  Are	  Midline	  Convexity	  Lesions	  
Representative	  pre-­‐operative	  MRI	  images	  of	  two	  SMARCB1-­‐mutant	  meningiomas,	  YALE-­‐251	  (A.)	  and	  
MUN-­‐MN-­‐301	  (B.).	  Note	  the	  midline	  location	  of	  these	  lesions.	  Both	  of	  these	  meningiomas	  are	  
parasagittal	  tumors.	  Similar	  MRI	  images	  and/or	  radiology	  reports	  detailing	  the	  location	  of	  all	  25	  


















Genetics	  of	  SMARCB1-­‐Mutant	  Meningiomas	  
	  
Here,	  we	  identified	  25	  meningiomas	  that	  harbored	  somatic	  SMARCB1	  mutations	  
(772	  meningiomas	  were	  analyzed	  in	  total).	  These	  tumors	  represent	  a	  genetically	  
and	  phenotypically	  distinct	  subgroup	  of	  NF2-­‐mutant	  /	  Chr22-­‐loss	  meningiomas.	  The	  
somatic	  SMARCB1	  mutations	  we	  identified	  can	  be	  categorized	  as	  one	  of	  three	  types.	  
The	  first	  two	  are	  recurrent	  point	  mutations	  affecting	  either	  amino	  acid	  386	  (R386H)	  
or	  amino	  acid	  383	  (R383Q)	  of	  the	  SMARCB1	  peptide;	  the	  third	  category	  constitutes	  
frameshift	  mutations.	  All	  25	  meningiomas	  with	  somatic	  SMARCB1	  mutations	  also	  
possessed	  concurrent	  somatic	  NF2-­‐mutaitons	  and/or	  somatic	  Chr22-­‐loss.	  	  
	  
RNA	  expression	  hierarchical	  clustering	  analysis	  demonstrated	  that	  SMARCB1-­‐
mutant	  meningiomas	  cluster	  within	  the	  NF2-­‐mutant	  superfamily	  (distinct	  from	  the	  
non-­‐NF2-­‐mutant	  meningiomas);	  however,	  these	  tumors	  appear	  to	  possess	  a	  distinct	  
expression	  pattern	  that	  differentiates	  them	  from	  non-­‐SMARCB1-­‐mutant	  NF2-­‐mutant	  
meningiomas.	  This	  sub-­‐group	  clustering	  pattern	  is	  due	  at	  least	  in	  part	  to	  increased	  
GLI1	  and	  EZH2	  expression	  in	  SMARCB1-­‐mutant	  meningiomas.	  	  
	  
GLI1	  is	  important	  effector	  of	  the	  hedgehog	  pathway	  (183).	  GLI1	  expression	  levels	  in	  
SMARCB1-­‐mutant	  meningiomas	  more	  closely	  resemble	  those	  in	  SMO-­‐mutant	  
meningiomas	  that	  were	  previously	  identified	  to	  drive	  tumorigenesis	  of	  
meningiomas	  of	  the	  olfactory	  groove	  (midline	  structure	  of	  the	  anterior	  skull	  base)	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(101).	  Expression	  levels	  of	  EZH2,	  a	  Polycomb-­‐group	  protein	  involved	  in	  epigenetic	  
modification	  (121,	  195),	  were	  also	  increased	  in	  SMARCB1-­‐mutant	  meningiomas	  
compared	  to	  non-­‐SMARCB1-­‐mutant	  NF2-­‐mutant	  meningiomas.	  	  
	  
Whole-­‐genome	  genotyping	  analysis	  demonstrated	  that	  SMARCB1-­‐mutant	  
meningiomas	  are	  largely	  chromosomally	  stable	  –	  only	  2	  out	  of	  the	  10	  analyzed	  
demonstrated	  a	  large-­‐scale	  chromosomal	  deletion	  or	  amplification	  aside	  from	  
Chr22q-­‐loss.	  Interestingly,	  this	  holds	  true	  even	  for	  the	  high-­‐grade	  SMARCB1-­‐mutant	  
meningiomas	  analyzed.	  Across	  various	  tumor	  types,	  chromosomal	  instability	  is	  
traditionally	  considered	  a	  hallmark	  of	  high-­‐grade	  lesions.	  However,	  of	  the	  4	  high-­‐
grade,	  SMARCB1-­‐mutant	  meningiomas	  we	  analyzed,	  only	  one	  (25%)	  possessed	  any	  
large-­‐scale	  chromosomal	  events	  (MUN-­‐MN-­‐295	  had	  a	  large-­‐scale	  Chr8p	  
amplification)	  aside	  from	  Chr22q-­‐loss;	  no	  focal	  chromosomal	  aberrations	  were	  
identified	  in	  these	  4	  samples.	  For	  comparison,	  29	  of	  32	  non-­‐SMARCB1-­‐mutant	  NF2-­‐
mutant	  high-­‐grade	  meningiomas	  in	  our	  database	  possessed	  large-­‐scale	  




Clinical	  Characteristics	  of	  SMARCB1-­‐Mutant	  Meningiomas	  
	  
Paralleling	  the	  genetic	  data,	  SMARCB1-­‐mutant	  tumors	  also	  appear	  to	  constitute	  a	  
distinct	  phenotypic	  sub-­‐group	  of	  NF2-­‐mutant	  meningiomas.	  Both	  the	  age	  at	  surgical	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intervention	  (median	  =	  64	  years)	  and	  female	  predominance	  (20	  /	  25;	  80%)	  in	  our	  
cohort	  are	  in	  accordance	  with	  the	  demographics	  previously	  reported	  (1).	  The	  
majority	  of	  concurrently	  SMARCB1-­‐mutant	  meningiomas	  (67%)	  were	  identified	  in	  
areas	  previously	  associated	  with	  NF2-­‐mutatant	  meningiomas	  –	  convexity,	  spinal	  
cord,	  and	  cerebellopontine	  angle	  (101).	  However,	  SMARCB1-­‐mutant	  meningiomas	  
demonstrated	  a	  strong	  tendency	  to	  form	  along	  the	  midline.	  Seventy-­‐one	  percent	  of	  
the	  SMARCB1-­‐mutant	  meningiomas	  were	  identified	  as	  parasagittal	  or	  parafalcine	  
convexity	  tumors	  or	  as	  occurring	  along	  the	  midline	  of	  the	  anterior	  skull	  base.	  
Therefore,	  similarly	  to	  the	  mutation-­‐location	  correlations	  described	  by	  Clark	  et	  al.	  
for	  anterior	  skull	  base	  meningiomas,	  a	  “mutation	  map”	  for	  convexity	  lesions	  also	  
appears	  to	  exist	  (101).	  In	  addition	  to	  the	  anterior-­‐posterior	  TRAF7	  –	  NF2	  mutation	  
gradient	  (described	  by	  Clark	  et	  al.	  and	  replicated	  in	  this	  study),	  a	  lateral-­‐medial-­‐
lateral	  “map”	  for	  SMARCB1-­‐mutant	  tumors	  also	  exists.	  See	  Figure	  5.	  Additionally,	  
SMARCB1-­‐mutant	  meningiomas	  demonstrated	  an	  increased	  propensity	  be	  
diagnosed	  as	  high-­‐grade	  lesions	  at	  time	  of	  initial	  resection	  (36%)	  compared	  to	  data	  











Figure	  5.	  “Mutation-­‐Map”	  for	  Convexity	  Meningiomas	  
A	  multi-­‐tiered	  mutation-­‐location	  gradient	  appears	  to	  exist	  for	  convexity	  meningiomas.	  Posterior	  
meningiomas	  tend	  to	  harbor	  NF2-­‐mutations	  and/or	  NF2	  /	  Chr22-­‐loss	  while	  TRAF7-­‐mutant	  convexity	  
meningiomas	  appear	  to	  be	  predominantly	  anteriorly	  –	  this	  observation	  was	  first	  reported	  by	  Clark	  et	  
al.	  and	  was	  replicated	  in	  this	  study.	  Additionally,	  a	  lateral-­‐medial-­‐lateral	  lesion	  gradient	  also	  exists	  
with	  respect	  to	  SMARCB1	  mutations.	  SMARCB1-­‐mutant	  meningiomas	  are	  predominantly	  midline	  







Genetic-­‐Clinical	  Correlates	  for	  SMARCB1-­‐Mutant	  Meningiomas	  
	  
Aberrant	  Hedgehog	  Signaling	  and	  Midline	  Tumor	  Location	  	  
	  
We	  found	  that	  the	  majority	  of	  SMARCB1-­‐mutant	  meningiomas	  were	  midline	  tumors.	  
Interestingly,	  we	  also	  found	  that	  SMARCB1-­‐mutant	  meningiomas	  demonstrated	  
increased	  GLI1	  expression	  relative	  to	  both	  normal	  meningeal	  control	  tissue	  and	  
non-­‐SMARCB1-­‐mutant	  NF2-­‐mutant	  meningiomas.	  GLI1	  is	  an	  important	  effector	  of	  
the	  Hedgehog	  pathway	  and	  plays	  key	  roles	  during	  embryogenesis,	  especially	  with	  
the	  development	  and	  patterning	  of	  midline	  structures	  (174,	  175,	  183).	  These	  
findings	  are	  consistent	  with	  data	  previously	  published	  demonstrating	  that	  that	  the	  
SWI/SNF	  complex,	  and	  the	  SMARCB1	  component	  specifically,	  interact	  with	  the	  
Hedgehog	  pathway	  via	  GLI1	  (183-­‐185).	  Similarly	  to	  our	  results,	  this	  study	  found	  
that	  loss	  of	  SMARCB1	  resulted	  in	  aberrant	  upregulation	  of	  the	  Hedgehog	  pathway	  
and	  increased	  GLI1	  expression	  (183).	  Given	  the	  importance	  of	  the	  Hedgehog	  
pathway	  in	  patterning	  the	  midline	  (174,	  175),	  it	  is	  intriguing	  that	  SMARCB1-­‐mutant	  
meningiomas	  were	  primarily	  found	  to	  occur	  along	  the	  midline	  of	  both	  the	  convexity	  
and	  anterior	  skull	  base.	  In	  fact,	  GLI1	  expression	  levels	  in	  SMARCB1-­‐mutant	  
meningiomas	  more	  closely	  resemble	  GLI1	  levels	  found	  in	  the	  SMO-­‐mutant	  
meningiomas	  that	  form	  along	  the	  olfactory	  groove	  in	  the	  anterior	  skull	  base	  (101).	  
We	  hypothesize	  that	  deregulation	  of	  the	  Hedgehog	  pathway	  results	  in	  the	  
predilection	  of	  these	  meningiomas	  to	  occur	  along	  the	  midline.	  Further,	  these	  results	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are	  consistent	  with	  a	  previous	  study	  that	  demonstrated	  that	  germline	  SMARCB1	  
mutations	  were	  associated	  with	  the	  development	  of	  parafalcine	  meningiomas	  (99).	  
	  
	  
Increased	  EZH2	  Expression	  and	  High-­‐Grade	  Predilection	  
	  
We	  found	  that	  a	  considerable	  percentage	  (36%)	  of	  SMARCB1-­‐mutant	  meningiomas	  
were	  identified	  as	  de	  novo	  high-­‐grade	  –	  this	  is	  a	  greater	  percentage	  than	  is	  often	  
reported	  in	  the	  literature	  (5-­‐7).	  Interestingly,	  whole-­‐genome	  genotyping	  analysis	  
demonstrated	  that	  these	  high-­‐grade	  SMARCB1-­‐mutant	  lesions	  possessed	  
remarkable	  chromosomal	  stability	  compared	  to	  non-­‐SMARCB1-­‐mutant	  NF2-­‐mutant	  
high-­‐grade	  lesions	  analyzed	  in	  our	  cohort.	  While	  chromosomal	  instability	  is	  
typically	  considered	  a	  hallmark	  of	  high-­‐grade	  lesions	  across	  many	  tumor	  types,	  
these	  SMARCB1-­‐mutant	  meningiomas	  appear	  to	  progress	  to	  high-­‐grade	  lesions	  via	  
some	  other	  mechanism	  (187).	  These	  data	  are	  consistent	  with	  previous	  work	  that	  
demonstrated	  that	  highly	  malignant	  rhabdoid	  tumors	  that	  result	  from	  SMARCB1	  
mutations	  demonstrate	  remarkably	  stable	  genomes,	  harboring	  relatively	  few	  
genetic	  point	  mutations	  or	  chromosomal	  alterations,	  especially	  for	  such	  an	  
aggressive	  tumor	  type	  (165).	  One	  mechanism	  by	  which	  these	  SMARCB1-­‐mutant	  
tumors	  may	  progress	  to	  high-­‐grade	  lesions	  without	  widespread	  genomic	  mutations	  
or	  chromosomal	  instability	  is	  via	  epigenetic	  modifications	  –	  either	  via	  gene	  
methylation	  or	  histone	  modification.	  SMARCB1	  and	  the	  SWI/SNF	  complex	  are	  
capable	  of	  remodeling	  chromatin	  via	  ATP-­‐dependent	  nucleosome	  modulation	  (119-­‐
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121).	  Interestingly,	  we	  also	  found	  that	  SMARCB1-­‐mutant	  meningiomas	  possessed	  
increased	  EZH2	  expression	  compared	  to	  both	  normal	  meningeal	  control	  tissue	  and	  
non-­‐SMARCB1-­‐mutant	  NF2-­‐mutant	  meningiomas.	  EZH2	  is	  a	  member	  of	  the	  
Polycomb-­‐group	  proteins	  that	  is	  capable	  of	  epigenetically	  silencing	  the	  expression	  
of	  a	  gene	  via	  histone	  methylation,	  resulting	  in	  chromatin	  remodeling	  (188-­‐190).	  
Previous	  studies	  have	  indeed	  demonstrated	  that	  the	  SWI/SNF	  complex,	  and	  the	  
SMARCB1	  component	  specifically,	  interacts	  with	  EZH2	  and	  other	  Polycomb-­‐group	  
proteins	  (191-­‐194).	  These	  epigenetic	  modifications,	  either	  directly	  resulting	  from	  
aberrant	  function	  of	  the	  SWI/SNF	  complex	  or	  via	  deregulation	  of	  EZH2	  expression,	  
may	  allow	  affected	  cells	  to	  regress	  to	  a	  more	  de-­‐differentiated	  state	  and	  progress	  to	  
high-­‐grade	  lesions	  even	  in	  the	  absence	  of	  widespread	  genomic	  instability.	  
	  
Taken	  together,	  these	  results	  demonstrate	  that	  SMARCB1-­‐mutant	  meningiomas	  
represent	  a	  genetically	  and	  phenotypically	  distinct	  sub-­‐group	  of	  NF2-­‐mutant	  
meningiomas	  and	  partially	  contribute	  to	  the	  observed	  clinical	  heterogeneity	  of	  
convexity	  lesions.	  	  
	  
	  
Treatment	  Implications	  and	  Future	  Directions	  
	  
The	  ultimate	  goal	  of	  these	  genetic	  analyses	  is	  to	  help	  identify	  potential	  therapeutic	  
targets	  and	  enhance	  our	  capacity	  to	  detect	  meningiomas	  with	  an	  increased	  
propensity	  to	  recur	  following	  surgical	  treatment	  or	  progress	  to	  high-­‐grade	  lesions.	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These	  results	  suggest	  potential	  targets	  for	  therapeutic	  intervention	  and	  help	  lay	  the	  
foundation	  for	  future	  studies	  to	  determine	  if	  individualized	  therapies	  may	  be	  
efficacious	  for	  patients	  with	  SMARCB1-­‐mutant	  meningiomas.	  	  
	  
The	  first	  targetable	  option	  that	  may	  warrant	  future	  exploration	  would	  be	  the	  
Hedgehog	  pathway.	  Our	  results	  demonstrated	  that	  SMARCB1-­‐mutant	  meningiomas	  
demonstrate	  increased	  GLI1	  expression	  and	  possible	  deregulation	  of	  the	  Hedgehog	  
pathway	  that	  may	  account	  for	  the	  predilection	  of	  these	  tumors	  to	  occur	  along	  the	  
midline.	  Midline	  tumors	  of	  both	  the	  convexity	  and	  skull	  base	  can	  be	  difficult	  to	  safely	  
cure	  surgically	  due	  to	  encasement	  or	  involvement	  of	  critical	  vessels	  and	  structures	  
including	  the	  superior	  sagittal	  sinus	  and	  pericallosal	  arteries.	  In	  these	  cases,	  
adjuvant	  chemotherapeutic	  options	  may	  prove	  helpful	  in	  tumor	  treatment.	  Many	  
Hedgehog	  pathway	  inhibitors	  exist	  and	  are	  being	  used	  in	  FDA-­‐approved	  clinical	  
trials	  (data	  from	  https://clinicaltrials.gov/).	  Future	  studies	  are	  needed	  to	  determine	  
if	  such	  an	  inhibitor	  may	  be	  capable	  of	  inhibiting	  tumor	  growth,	  recurrence,	  or	  
progression	  in	  SMARCB1-­‐mutant	  meningiomas.	  	  
	  
A	  second	  potential	  therapeutic	  target	  is	  EZH2.	  We	  have	  demonstrated	  that	  
SMARCB1-­‐mutant	  meningiomas	  trend	  to	  having	  a	  predilection	  of	  being	  high-­‐grade	  at	  
time	  of	  initial	  surgery.	  High-­‐grade	  meningiomas	  have	  significantly	  increased	  
recurrence	  rates	  and	  significantly	  more	  grave	  prognoses	  (5,	  11-­‐13).	  One	  factor	  
contributing	  to	  the	  poor	  prognosis	  carried	  by	  the	  high-­‐grade	  meningiomas	  is	  the	  
lack	  of	  effective	  chemotherapeutic	  therapies	  to	  supplement	  surgical	  intervention	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(14).	  Here,	  we	  found	  that	  SMARCB1-­‐mutant	  meningiomas	  have	  increased	  EZH2	  
levels.	  Increased	  EZH2	  expression	  may	  serve	  as	  a	  substitute	  for	  widespread	  
genomic	  instability	  and	  contribute	  to	  the	  progression	  of	  these	  tumors	  to	  high-­‐grade	  
lesions	  (187).	  Therefore,	  EZH2	  inhibitors	  may	  be	  an	  efficacious	  chemotherapeutic	  
option	  for	  patients	  found	  to	  have	  a	  high-­‐grade	  SMARCB1-­‐mutant	  meningioma.	  As	  
was	  true	  for	  the	  Hedgehog	  pathway	  inhibitors,	  numerous	  EZH2	  inhibitors	  already	  
exist	  and	  are	  being	  used	  in	  FDA-­‐approved	  clinical	  trials	  (data	  from	  
https://clinicaltrials.gov/).	  Again,	  future	  studies	  are	  needed	  to	  determine	  if	  such	  an	  
inhibitor	  may	  be	  capable	  of	  inhibiting	  tumor	  growth,	  recurrence,	  or	  progression	  in	  
SMARCB1-­‐mutant	  meningiomas.	  
	  
An	  additional	  area	  of	  future	  study	  may	  be	  the	  potential	  role	  of	  radiation	  therapy	  for	  
patients	  with	  high-­‐grade	  SMARCB1-­‐mutant	  meningiomas.	  Radiation	  therapy	  has	  
been	  used	  as	  an	  adjuvant	  to	  surgical	  resection	  of	  meningiomas;	  however,	  its	  use	  
remains	  controversial	  (9,	  10,	  12,	  23).	  One	  of	  the	  primary	  concerns	  is	  that	  radiation	  
therapy	  may	  induce	  further	  genomic	  instability	  and	  contribute	  to	  malignant	  
progression	  of	  these	  tumors.	  In	  other	  words,	  in	  high-­‐grade	  tumors	  that	  already	  
possess	  numerous	  point	  mutations	  and	  widespread	  chromosomal	  instability	  yet	  are	  
able	  continue	  to	  proliferate,	  inducing	  additional	  point	  mutations	  and	  chromosomal	  
aberrations	  via	  radiation	  therapy	  may	  only	  serve	  to	  contribute	  to	  malignant	  
progression.	  However,	  we	  found	  that	  high-­‐grade	  meningiomas	  that	  harbor	  
SMARCB1	  mutations	  possess	  remarkably	  stable	  genomes	  with	  relatively	  few	  point	  
mutations	  or	  large-­‐scale	  chromosomal	  aberrations.	  Therefore,	  it	  is	  possible	  that	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these	  tumors	  may	  be	  amenable	  to	  radiation	  therapy	  with	  relatively	  little	  risk	  of	  
significant	  malignant	  progression.	  	  
In	  addition	  to	  these	  clinical	  areas	  of	  future	  study,	  further	  work	  is	  needed	  to	  better	  
understand	  the	  role	  and	  elucidate	  the	  precise	  mechanisms	  by	  which	  SMARCB1	  
mutations	  contribute	  to	  meningioma	  formation.	  Further,	  additional	  work	  is	  needed	  
to	  identify	  other	  concurrently	  mutated	  genes	  and/or	  epigenetic	  modifications	  that	  





In	  summary,	  we	  identified	  somatic	  SMARCB1	  mutations	  in	  a	  subset	  of	  concurrently	  
NF2-­‐mutant	  intracranial	  meningiomas.	  These	  SMARCB1-­‐mutant	  meningiomas	  
represent	  a	  distinct	  genetic	  and	  phenotypic	  sub-­‐group	  of	  NF2-­‐mutant	  meningiomas.	  
These	  tumors	  primarily	  occur	  along	  the	  midline	  –	  possibly	  due	  to	  aberrant	  
hedgehog	  signaling	  and	  increased	  GLI1	  expression	  –	  and	  have	  an	  increased	  
propensity	  to	  be	  de	  novo	  high-­‐grade	  lesions	  despite	  having	  remarkably	  stable	  
genomes	  –	  possibly	  due	  to	  epigenetic	  alterations	  due	  to	  increased	  EZH2	  expression.	  
These	  results	  help	  to	  account	  for	  some	  of	  the	  observed	  clinical	  heterogeneity	  of	  NF2-­‐
mutant	  meningiomas.	  Further,	  these	  findings	  suggest	  potential	  targets	  for	  
therapeutic	  interventions	  that	  warrant	  future	  investigation.	  	  




Table	  A1.	  Whole-­‐Genome	  Genotyping	  Results	  for	  Non-­‐SMARCB1-­‐Mutant	  NF2-­‐
Mutant	  High-­‐Grade	  Meningiomas	  
	  
Tumor	  




























BONN-­‐T-­‐1134	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	   22q	   None	   None	   None	   None	   None	  
BONN-­‐T-­‐1766	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	   19q	   19p	   None	   None	  
19p	  /	  
22q	   None	  
BONN-­‐T-­‐2492	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	   19p	  /	  22q	   None	   None	   None	   None	   16p	  
BONN-­‐T-­‐2857	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	   7p	  /	  22q	   None	   7q	   None	   None	   5p	  /	  16p	  
BONN-­‐T-­‐2936	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  9p	  /	  
12p	  /	  19p	  /	  
22q	  
None	   None	   None	   None	   None	  
BONN-­‐T-­‐2983	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	   14q	  /	  22q	   16p	   None	   None	   None	   None	  
BONN-­‐T-­‐3811	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  8p	  /	  8q	  
/	  14q	  /	  22q	   None	   None	   None	   None	   None	  
BONN-­‐T-­‐4243	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  4p	  /	  4q	  
/	  6q	  /	  18p	  /	  
18q	  /	  22q	  
None	   7p	   None	   None	   None	  
BONN-­‐T-­‐4526	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	   None	  
1p	  /	  2p	  /	  2q	  
/	  3p	  /	  3q	  /	  
4p	  /	  4q	  /	  5p	  
/	  5q	  /	  6p	  /	  
6q	  /	  7p	  /	  7q	  
/	  8p	  /	  8q	  /	  
10p	  /	  10q	  /	  
11p	  /	  11q	  /	  
12p	  /	  12q	  /	  
13q	  /	  14q	  /	  
16p	  /	  18p	  /	  
18q	  /	  21q	  /	  
22q	  
None	   16p	   22q	   20p	  
BONN-­‐T-­‐4530	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  1q	  /	  4p	  
/	  4q	  /	  6p	  /	  
6q	  /	  14q	  /	  
22q	  
None	   20p	  /	  20q	   None	   None	   16p	  
BONN-­‐T-­‐4560	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	   22q	   None	   14q	   None	   None	   14q	  
BONN-­‐T-­‐4705	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  6p	  /	  6q	  
/	  14q	  /	  22q	   None	   None	   None	   None	   None	  
BONN-­‐T-­‐4760	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  6q	  /	  
14q	  /	  17p	  /	  
18p	  /	  18q	  /	  
22q	  
13q	   1q	  /	  13q	   17q	   None	   16p	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BONN-­‐T-­‐4846	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	   22q	   None	   None	   None	   7p	   7q	  /	  14q	  
BONN-­‐T-­‐590	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	   14q	  /	  22q	   None	   None	   None	  
11p	  /	  
19q	   None	  
BONN-­‐T-­‐83	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  7p	  /	  9p	  
/	  10p	  /	  10q	  
/	  14q	  /	  18q	  
/	  22q	  
None	   1q	   3q	   None	   None	  
MUN-­‐MN-­‐164	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  2p	  /	  7p	  
/	  7q	  /	  18p	  /	  
18q	  /	  22q	  
None	  
3p	  /	  3q	  
/	  5p	  /	  
5q	  /	  8p	  




6p	  /	  6q	  





9q	  /	  20p	  
MUN-­‐MN-­‐171	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  10p	  /	  
10q	  /	  14q	  /	  
18p	  /	  18q	  /	  
22q	  
None	   13q	   1q	   None	   None	  
MUN-­‐MN-­‐22	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	   22q	   None	   None	   None	   None	   16p	  
MUN-­‐MN-­‐298	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  12p	  /	  
22q	   None	   None	   None	   None	   None	  
MUN-­‐MN-­‐54	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  18q	  /	  
19p	  /	  22q	   None	   None	   None	   None	   None	  
MUN-­‐MN-­‐96	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  6p	  /	  6q	  
/	  10q	  /	  12q	  
/	  14q	  /	  19p	  
/	  22q	  
10p	   10p	   9q	   8p	  
8q	  /	  10p	  
/	  10q	  /	  
14q	  /	  
19p	  
MUN-­‐MN-­‐97	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  6p	  /	  6q	  
/	  7p	  /	  10p	  /	  
10q	  /	  14q	  /	  
22q	  
None	   None	   None	   2p	  /	  11p	   10q	  /	  19p	  
YALE-­‐54	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  2q	  /	  3p	  
/	  6q	  /	  22q	   4q	   None	   None	   None	   None	  
YALE-­‐67	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  3p	  /	  8p	  
/	  8q	  /	  9p	  /	  
19p	  /	  22q	  
None	   None	   None	   None	   None	  
YALE-­‐83	   NF2-­‐mutant	  /	  Chr22-­‐loss	   Wildtype	   2	  
1p	  /	  6q	  /	  






None	   None	   17q	  
	  
Chr	  =	  Chromosomal	  
Amp.	  =	  Amplification	  
LOH	  =	  Loss	  of	  Heterozygosity	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Table	  A2.	  Top	  300	  Differentially	  Expressed	  Genes	  Between	  SMARCB1-­‐Mutant	  













































SCG2	   10.529	   8.097	   2.432	  
	  
KRT18	   7.634	   9.683	   -­‐2.049	  
RSPO3	   9.684	   7.328	   2.356	  
	  
FLJ40504	   6.623	   8.643	   -­‐2.020	  
FNDC1	   7.521	   5.306	   2.215	  
	  
NDUFA4L2	   8.063	   9.923	   -­‐1.860	  
NNMT	   9.137	   7.206	   1.931	  
	  
PFKP	   6.191	   7.872	   -­‐1.681	  
FBLN1	   11.381	   9.481	   1.900	  
	  
IGFBP3	   7.323	   8.869	   -­‐1.546	  
SFRP1	   10.779	   8.913	   1.866	  
	  
LUM	   5.707	   7.205	   -­‐1.497	  
TNC	   8.652	   6.805	   1.847	  
	  
C4orf31	   6.947	   8.421	   -­‐1.474	  
SRPX	   8.870	   7.193	   1.677	  
	  
EFNB2	   7.223	   8.688	   -­‐1.465	  
RBP4	   7.043	   5.439	   1.604	  
	  
IGF2	   6.786	   8.249	   -­‐1.463	  
FAM164C	   9.959	   8.388	   1.571	  
	  
HOPX	   6.997	   8.457	   -­‐1.460	  
HP	   6.723	   5.160	   1.562	  
	  
SCG5	   5.349	   6.779	   -­‐1.430	  
C13orf36	   7.041	   5.534	   1.507	  
	  
PVALB	   4.745	   6.164	   -­‐1.420	  
RUNX3	   7.927	   6.426	   1.502	  
	  
DAPL1	   4.940	   6.341	   -­‐1.401	  
IGF1	   7.575	   6.097	   1.478	  
	  
PERP	   6.202	   7.593	   -­‐1.391	  
COL8A1	   11.650	   10.248	   1.402	  
	  
DIRAS2	   5.603	   6.978	   -­‐1.376	  
VIT	   6.726	   5.396	   1.330	  
	  
DCN	   6.429	   7.795	   -­‐1.366	  
ODZ3	   10.326	   9.023	   1.303	  
	  
SEZ6L2	   7.444	   8.806	   -­‐1.362	  
ALPL	   10.152	   8.851	   1.301	  
	  
SYBU	   7.947	   9.295	   -­‐1.348	  
CD177	   6.229	   4.970	   1.259	  
	  
VTN	   6.175	   7.510	   -­‐1.335	  
SLPI	   11.029	   9.781	   1.248	  
	  
PHLDA1	   5.691	   7.010	   -­‐1.319	  
MATN2	   10.263	   9.045	   1.217	  
	  
TF	   6.286	   7.602	   -­‐1.316	  
EGFL6	   11.910	   10.703	   1.207	  
	  
CDKN2C	   6.370	   7.667	   -­‐1.297	  
CHN2	   8.465	   7.272	   1.193	  
	  
NECAB1	   7.713	   8.996	   -­‐1.283	  
ROR1	   8.183	   6.997	   1.186	  
	  
AGR2	   4.696	   5.971	   -­‐1.276	  
HOXC8	   6.543	   5.358	   1.185	  
	  
GJB6	   6.801	   8.076	   -­‐1.275	  
C21orf81	   8.323	   7.150	   1.174	  
	  
LINGO2	   5.058	   6.302	   -­‐1.244	  
RYR3	   5.963	   4.803	   1.160	  
	  
NPNT	   7.402	   8.642	   -­‐1.240	  
GFRA1	   8.182	   7.030	   1.152	  
	  
APOD	   8.179	   9.419	   -­‐1.240	  
GDF10	   6.945	   5.798	   1.147	  
	  
RPS4Y1	   5.784	   7.015	   -­‐1.230	  
MRAP2	   7.923	   6.777	   1.145	  
	  
ANGPT2	   5.647	   6.867	   -­‐1.220	  
CR622072	   9.250	   8.107	   1.143	  
	  
CAMK2N1	   7.052	   8.226	   -­‐1.174	  
TNNC1	   10.882	   9.746	   1.136	  
	  
STC2	   5.102	   6.267	   -­‐1.165	  
NXPH2	   8.746	   7.621	   1.125	  
	  
H19	   8.390	   9.543	   -­‐1.152	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ZBTB7C	   8.409	   7.285	   1.124	  
	  
APOLD1	   7.097	   8.228	   -­‐1.131	  
COL8A2	   9.843	   8.728	   1.115	  
	  
ATP1A2	   4.865	   5.985	   -­‐1.121	  
BCAR3	   8.242	   7.132	   1.109	  
	  
PDGFRA	   4.861	   5.957	   -­‐1.096	  
PRRX1	   10.647	   9.539	   1.108	  
	  
CA3	   5.815	   6.906	   -­‐1.091	  
HOXC9	   5.911	   4.815	   1.095	  
	  
NEBL	   6.045	   7.130	   -­‐1.085	  
NTN1	   8.801	   7.717	   1.085	  
	  
PDLIM1	   6.443	   7.527	   -­‐1.084	  
MYOZ3	   8.369	   7.292	   1.077	  
	  
CFI	   7.528	   8.585	   -­‐1.057	  
KIAA1644	   6.722	   5.649	   1.073	  
	  
C1QTNF1	   7.958	   9.010	   -­‐1.052	  
ACAN	   5.846	   4.777	   1.069	  
	  
PDE5A	   7.877	   8.919	   -­‐1.042	  
CNTN3	   6.580	   5.513	   1.067	  
	  
RELN	   4.535	   5.569	   -­‐1.034	  
XIST	   8.396	   7.328	   1.067	  
	  
BMP6	   6.412	   7.444	   -­‐1.033	  
TGFB3	   9.006	   7.960	   1.046	  
	  
PDE7B	   5.853	   6.884	   -­‐1.031	  
SLC35F2	   7.317	   6.274	   1.043	  
	  
RNASE1	   8.029	   9.056	   -­‐1.027	  
PODXL2	   7.460	   6.424	   1.036	  
	  
PAPLN	   6.442	   7.457	   -­‐1.015	  
DUOX1	   6.610	   5.577	   1.033	  
	  
FREM2	   4.684	   5.694	   -­‐1.010	  
SMAD9	   8.198	   7.177	   1.021	  
	  
CXCL12	   6.785	   7.791	   -­‐1.006	  
NDRG4	   6.885	   5.864	   1.021	  
	  
MET	   6.739	   7.741	   -­‐1.002	  
FABP5	   10.854	   9.834	   1.021	  
	  
SLC26A2	   7.702	   8.702	   -­‐1.000	  
SORCS2	   6.937	   5.917	   1.020	  
	  
FOLR2	   6.689	   7.688	   -­‐0.999	  
DLL1	   7.289	   6.273	   1.016	  
	  
KCNT2	   5.592	   6.587	   -­‐0.995	  
NT5DC2	   8.711	   7.696	   1.015	  
	  
EIF1AY	   4.755	   5.745	   -­‐0.990	  
CDH23	   9.482	   8.488	   0.994	  
	  
HEY1	   6.179	   7.169	   -­‐0.989	  
FAM180B	   7.407	   6.414	   0.993	  
	  
SLC7A2	   9.660	   10.639	   -­‐0.979	  
KLK7	   5.946	   4.958	   0.988	  
	  
KCNJ8	   7.180	   8.157	   -­‐0.977	  
MFAP5	   11.482	   10.497	   0.985	  
	  
RHOJ	   5.507	   6.472	   -­‐0.965	  
FAM132A	   6.384	   5.400	   0.984	  
	  
PTGDS	   11.527	   12.479	   -­‐0.952	  
PXDN	   8.773	   7.797	   0.977	  
	  
GJA3	   4.432	   5.383	   -­‐0.951	  
IL20RA	   5.799	   4.825	   0.974	  
	  
SIPA1L2	   6.469	   7.415	   -­‐0.946	  
FAM107B	   9.295	   8.323	   0.972	  
	  
PPP1R1B	   5.078	   6.023	   -­‐0.945	  
SLC6A4	   5.603	   4.632	   0.971	  
	  
GAP43	   6.238	   7.181	   -­‐0.943	  
ISM1	   7.262	   6.290	   0.971	  
	  
AHNAK2	   7.291	   8.232	   -­‐0.941	  
TRIM9	   5.922	   4.960	   0.962	  
	  
NR3C2	   6.042	   6.982	   -­‐0.940	  
ROBO3	   8.044	   7.082	   0.962	  
	  
SNAR-­‐A3	   5.676	   6.614	   -­‐0.938	  
PRPH	   6.506	   5.545	   0.962	  
	  
COL18A1	   6.042	   6.973	   -­‐0.932	  
HPR	   6.905	   5.948	   0.957	  
	  
DCLK1	   5.930	   6.862	   -­‐0.932	  
HAPLN3	   5.977	   5.035	   0.942	  
	  
RAPGEF5	   5.823	   6.748	   -­‐0.925	  
MT1E	   9.808	   8.866	   0.942	  
	  
APCDD1	   5.876	   6.796	   -­‐0.920	  
MFGE8	   11.758	   10.819	   0.938	  
	  
AGT	   4.969	   5.884	   -­‐0.915	  
CTXN3	   9.070	   8.134	   0.935	  
	  
STRA6	   4.574	   5.483	   -­‐0.908	  
TMEM158	   9.150	   8.219	   0.932	  
	  
PDE8B	   6.546	   7.451	   -­‐0.905	  
TSPAN11	   5.934	   5.003	   0.931	  
	  
RAB27B	   4.366	   5.255	   -­‐0.888	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COL23A1	   6.023	   5.092	   0.931	  
	  
PLTP	   5.992	   6.865	   -­‐0.873	  
TOX2	   7.703	   6.777	   0.925	  
	  
MAPK4	   4.984	   5.856	   -­‐0.872	  
MYLK	   8.037	   7.116	   0.922	  
	  
WDR86	   8.249	   9.103	   -­‐0.855	  
HEG1	   9.178	   8.259	   0.919	  
	  
FAM179A	   5.094	   5.946	   -­‐0.852	  
SLCO3A1	   7.575	   6.664	   0.911	  
	  
TPM2	   10.467	   11.319	   -­‐0.852	  
NELL1	   6.218	   5.307	   0.911	  
	  
ACTG2	   6.129	   6.980	   -­‐0.851	  
SNAP91	   7.530	   6.619	   0.911	  
	  
HSD17B2	   5.652	   6.502	   -­‐0.849	  
DLGAP2	   5.934	   5.025	   0.909	  
	  
PRKAG2	   7.137	   7.982	   -­‐0.845	  
RNF144A	   6.818	   5.916	   0.903	  
	  
TFPI	   5.009	   5.850	   -­‐0.841	  
ATP1B1	   10.519	   9.617	   0.902	  
	  
KCNK1	   4.842	   5.680	   -­‐0.837	  
ST8SIA1	   6.750	   5.852	   0.897	  
	  
EDN3	   4.479	   5.312	   -­‐0.833	  
IL17RB	   6.271	   5.379	   0.892	  
	  
F3	   7.292	   8.124	   -­‐0.833	  
CLIC3	   9.721	   8.830	   0.891	  
	  
TNFRSF11B	   7.284	   8.116	   -­‐0.832	  
ODZ4	   8.323	   7.438	   0.885	  
	  
C21orf62	   4.832	   5.662	   -­‐0.830	  
FAM180A	   5.783	   4.900	   0.883	  
	  
ALDH1A3	   4.668	   5.493	   -­‐0.825	  
NKD1	   6.327	   5.447	   0.880	  
	  
ELOVL2	   4.883	   5.708	   -­‐0.825	  
MYRIP	   5.632	   4.755	   0.877	  
	  
NLGN1	   5.633	   6.456	   -­‐0.824	  
EFHD1	   8.324	   7.448	   0.877	  
	  
ABCB1	   5.104	   5.927	   -­‐0.823	  
PPAP2B	   10.320	   9.444	   0.876	  
	  
ACHE	   4.959	   5.782	   -­‐0.823	  
FAM69C	   5.325	   4.458	   0.867	  
	  
RNFT2	   6.105	   6.916	   -­‐0.811	  
FZD9	   6.740	   5.877	   0.863	  
	  
OLFML2B	   8.281	   9.088	   -­‐0.807	  
NRXN2	   8.370	   7.509	   0.862	  
	  
F10	   6.067	   6.866	   -­‐0.799	  
MT1M	   6.970	   6.115	   0.855	  
	  
ADAMTS1	   5.159	   5.954	   -­‐0.795	  
C2orf55	   9.063	   8.209	   0.853	  
	  
LRRC17	   6.265	   7.059	   -­‐0.794	  
CDH5	   9.514	   8.664	   0.851	  
	  
LOC644936	   7.648	   8.441	   -­‐0.793	  
SLC39A14	   8.436	   7.588	   0.847	  
	  
ATP6V1G2	   5.588	   6.379	   -­‐0.791	  
NAV2	   8.137	   7.291	   0.845	  
	  
POSTN	   4.678	   5.451	   -­‐0.773	  
SHROOM3	   7.056	   6.211	   0.845	  
	  
AF385432	   5.400	   6.172	   -­‐0.772	  
MAMSTR	   6.952	   6.111	   0.842	  
	  
ISYNA1	   7.554	   8.320	   -­‐0.766	  
GLI1	   6.169	   5.329	   0.840	  
	  
BAMBI	   8.746	   9.512	   -­‐0.766	  
SHF	   7.372	   6.539	   0.832	  
	  
GAS2	   4.625	   5.389	   -­‐0.764	  
SERPINF1	   9.646	   8.815	   0.831	  
	  
S100A13	   5.282	   6.041	   -­‐0.759	  
KIF1A	   8.525	   7.696	   0.830	  
	  
SEMA3C	   6.586	   7.344	   -­‐0.759	  
SHC4	   7.782	   6.952	   0.830	  
	  
REEP2	   4.714	   5.472	   -­‐0.758	  
ST6GAL1	   10.971	   10.145	   0.826	  
	  
LAYN	   6.493	   7.245	   -­‐0.752	  
ANKRD20A4	   8.176	   7.356	   0.820	  
	  
F13A1	   6.537	   7.288	   -­‐0.751	  
SFRP4	   10.262	   9.445	   0.817	  
	  
LOC100131176	   5.000	   5.750	   -­‐0.750	  
RNF24	   7.276	   6.461	   0.815	  
	  
HYAL1	   6.444	   7.193	   -­‐0.749	  
SCARA5	   12.305	   11.494	   0.811	  
	  
IGSF5	   4.622	   5.370	   -­‐0.749	  
JAK2	   7.553	   6.745	   0.808	  
	  
PALMD	   5.708	   6.455	   -­‐0.747	  
SPON1	   7.072	   6.266	   0.806	  
	  
IL8	   5.241	   5.986	   -­‐0.745	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REEP1	   9.131	   8.331	   0.800	  
	  
CA8	   5.002	   5.744	   -­‐0.742	  
MXRA8	   8.542	   7.746	   0.796	  
	  
FAM134B	   7.214	   7.955	   -­‐0.741	  
CGNL1	   11.176	   10.382	   0.794	  
	  
LYVE1	   6.592	   7.332	   -­‐0.740	  
ATOH8	   8.516	   7.727	   0.789	  
	  
RCN1	   9.905	   10.640	   -­‐0.735	  
B4GALT1	   8.155	   7.369	   0.786	  
	  
TNFRSF12A	   5.920	   6.653	   -­‐0.733	  
MT1X	   10.102	   9.316	   0.786	  
	  
CFH	   7.439	   8.172	   -­‐0.733	  
NEUROG2	   6.399	   5.617	   0.782	  
	  
RCAN2	   6.184	   6.915	   -­‐0.731	  
CALML4	   9.113	   8.332	   0.782	  
	  
PANK1	   6.330	   7.060	   -­‐0.730	  
FGL2	   12.483	   11.713	   0.771	  
	  
FAM129A	   7.549	   8.271	   -­‐0.722	  
BOC	   8.818	   8.048	   0.770	  
	  
TMEM108	   6.529	   7.251	   -­‐0.722	  
CSRP2	   8.466	   7.702	   0.765	  
	  
BMP5	   8.093	   8.814	   -­‐0.721	  
PRDM6	   7.471	   6.708	   0.763	  
	  
GCNT2	   5.470	   6.189	   -­‐0.719	  
BBS9	   7.617	   6.855	   0.761	  
	  
C5orf30	   5.612	   6.329	   -­‐0.718	  
RAP1GAP	   6.849	   6.089	   0.760	  
	  
FLJ30375	   6.322	   7.039	   -­‐0.718	  
NEDD4L	   7.284	   6.527	   0.757	  
	  
S100A9	   5.728	   6.445	   -­‐0.717	  
IL11RA	   10.930	   10.176	   0.754	  
	  
HEY2	   5.378	   6.095	   -­‐0.717	  
RAB31	   11.203	   10.453	   0.751	  
	  
WFDC2	   5.001	   5.717	   -­‐0.716	  
ITGA11	   7.642	   6.892	   0.750	  
	  
CPS1	   6.297	   7.011	   -­‐0.714	  
AR	   7.110	   6.362	   0.748	  
	  
ISLR	   9.903	   10.616	   -­‐0.713	  
LDLRAD3	   5.962	   5.214	   0.747	  
	  
CXXC5	   8.344	   9.056	   -­‐0.712	  
MAP1B	   10.193	   9.447	   0.746	  
	  
PDE6A	   5.397	   6.107	   -­‐0.710	  
THBS4	   5.857	   5.111	   0.746	  
	  
SERPINA3	   6.623	   7.329	   -­‐0.706	  
CPT1C	   6.660	   5.914	   0.746	  
	  
CAV2	   6.003	   6.707	   -­‐0.704	  
C1QTNF4	   5.992	   5.247	   0.745	  
	  
ENPP5	   6.048	   6.750	   -­‐0.702	  
PIK3R1	   10.581	   9.841	   0.740	  
	  
LTBP4	   9.234	   9.935	   -­‐0.702	  
FAM38B	   8.165	   7.427	   0.738	  
	  
GPR83	   6.750	   7.450	   -­‐0.700	  
CYP4B1	   6.622	   5.888	   0.734	  
	  
CCND1	   11.669	   12.368	   -­‐0.699	  
ARHGEF3	   10.048	   9.317	   0.731	  
	  
ABCC9	   5.391	   6.089	   -­‐0.698	  
SLC38A8	   5.515	   4.785	   0.730	  
	  
ANGPT1	   5.620	   6.318	   -­‐0.698	  
RCN3	   7.928	   7.198	   0.730	  
	  
DHRS2	   4.472	   5.169	   -­‐0.697	  
CAB39L	   8.592	   7.863	   0.729	  
	  
TAGLN2	   8.675	   9.372	   -­‐0.697	  
TMEM59L	   6.720	   5.992	   0.728	  
	  
NXPH4	   4.807	   5.503	   -­‐0.696	  
EFS	   8.138	   7.410	   0.728	  
	  
SYTL4	   4.966	   5.661	   -­‐0.695	  
RUNX1	   7.482	   6.757	   0.725	  
	  
ALDH1A2	   6.278	   6.969	   -­‐0.691	  
CYP1B1	   11.347	   10.624	   0.723	  
	  
IGDCC4	   5.464	   6.155	   -­‐0.691	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Table	  A3.	  Comparison	  of	  Demographic	  Data	  Between	  SMARCB1-­‐Mutant	  and	  


























T-­‐1134	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   44	   F	   	  
BONN-­‐T-­‐
2758	   R386H	   NF2-­‐mutant	   2	   65	   M	  
BONN-­‐
T-­‐1766	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   70	   M	   	  
BONN-­‐T-­‐
314	   R383Q	  
Chr22q-­‐loss	  &	  
NF2-­‐mutant	   2	   49	   F	  
BONN-­‐
T-­‐2492	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   56	   F	   	  
BONN-­‐T-­‐
439	   R386H	   NF2-­‐mutant	   2	   72	   M	  
BONN-­‐
T-­‐2857	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   53	   M	   	  
BONN-­‐T-­‐
841	   R386H	   Chr22q-­‐loss	   2	   67	   M	  
BONN-­‐
T-­‐2936	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   66	   F	   	  
BONN-­‐T-­‐
847	   Frameshift	  	   NF2-­‐mutant	   2	   59	   F	  
BONN-­‐
T-­‐2983	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   76	   M	   	  
KOLN-­‐
HT-­‐2835	   Frameshift	  	   NF2-­‐mutant	   2	   73	   M	  
BONN-­‐
T-­‐3811	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   68	   M	   	  
MSK-­‐MN-­‐
500	   R386H	  
NF2-­‐loss	  &	  
NF2-­‐mutant	   2	   64	   F	  
BONN-­‐
T-­‐4243	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   86	   M	   	  
MUN-­‐MN-­‐
295	   Frameshift	  	   Chr22q-­‐loss	   2	   70	   F	  
BONN-­‐
T-­‐4526	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   64	   F	   	   YALE-­‐251	   R386H	   NF2-­‐loss	   2	   29	   F	  
BONN-­‐
T-­‐4530	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   54	   M	   	   	   	   	   	   	   	  
BONN-­‐
T-­‐4560	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   77	   F	   	   	   	   	   	   	   	  
BONN-­‐
T-­‐4705	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   94	   M	   	   	   	   	   	   	   	  
BONN-­‐
T-­‐4760	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   86	   M	   	   	   	   	   	   	   	  
BONN-­‐
T-­‐4846	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   78	   F	   	   	   	   	   	   	   	  
BONN-­‐
T-­‐590	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   63	   F	   	   	   	   	   	   	   	  
BONN-­‐
T-­‐83	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   56	   M	   	   	   	   	   	   	   	  
MUN-­‐
MN-­‐164	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   45	   F	   	   	   	   	   	   	   	  
MUN-­‐
MN-­‐171	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   53	   F	   	   	   	   	   	   	   	  
MUN-­‐
MN-­‐22	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   50	   F	   	   	   	   	   	   	   	  
MUN-­‐
MN-­‐298	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   23	   F	   	   	   	   	   	   	   	  
MUN-­‐
MN-­‐54	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   56	   M	   	   	   	   	   	   	  
MUN-­‐
MN-­‐96	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   76	   M	   	   	   	   	   	  
MUN-­‐
MN-­‐97	   Wildtype	  
NF2-­‐mutant	  
/	  Chr22-­‐loss	   2	   59	   M	   	   	   	   	   	  






YALE-­‐67	   Wildtype	   NF2-­‐mutant	  /	  Chr22-­‐loss	   2	   39	   F	   	   	   	   Median	  Age	   62	   65	  
YALE-­‐83	   Wildtype	   NF2-­‐mutant	  /	  Chr22-­‐loss	   2	   n/a	   F	   	   	   	   %	  Female	   54%	   55%	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